KR102243873B1 - Fermented pills for reducing and preventing premature dementia and manufacturing methods thereof - Google Patents
Fermented pills for reducing and preventing premature dementia and manufacturing methods thereof Download PDFInfo
- Publication number
- KR102243873B1 KR102243873B1 KR1020200112522A KR20200112522A KR102243873B1 KR 102243873 B1 KR102243873 B1 KR 102243873B1 KR 1020200112522 A KR1020200112522 A KR 1020200112522A KR 20200112522 A KR20200112522 A KR 20200112522A KR 102243873 B1 KR102243873 B1 KR 102243873B1
- Authority
- KR
- South Korea
- Prior art keywords
- fermented
- weight
- powder
- acupuncture
- parts
- Prior art date
Links
- 206010012289 Dementia Diseases 0.000 title claims abstract description 62
- 238000004519 manufacturing process Methods 0.000 title claims abstract description 15
- 239000006187 pill Substances 0.000 title claims abstract description 12
- 230000002028 premature Effects 0.000 title description 2
- 239000000843 powder Substances 0.000 claims abstract description 102
- 241000411851 herbal medicine Species 0.000 claims abstract description 31
- 239000012141 concentrate Substances 0.000 claims abstract description 28
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims abstract description 25
- 238000004898 kneading Methods 0.000 claims abstract description 12
- 238000001467 acupuncture Methods 0.000 claims description 58
- 239000000284 extract Substances 0.000 claims description 42
- 238000000855 fermentation Methods 0.000 claims description 37
- 230000004151 fermentation Effects 0.000 claims description 37
- 239000000463 material Substances 0.000 claims description 34
- 238000000034 method Methods 0.000 claims description 22
- 230000002265 prevention Effects 0.000 claims description 18
- 235000012907 honey Nutrition 0.000 claims description 16
- 238000002156 mixing Methods 0.000 claims description 16
- 210000003056 antler Anatomy 0.000 claims description 14
- 235000002789 Panax ginseng Nutrition 0.000 claims description 13
- 241000209020 Cornus Species 0.000 claims description 12
- 240000006079 Schisandra chinensis Species 0.000 claims description 12
- 235000008422 Schisandra chinensis Nutrition 0.000 claims description 12
- 210000004207 dermis Anatomy 0.000 claims description 11
- 235000006886 Zingiber officinale Nutrition 0.000 claims description 10
- 235000008397 ginger Nutrition 0.000 claims description 10
- 241000193830 Bacillus <bacterium> Species 0.000 claims description 9
- 238000001035 drying Methods 0.000 claims description 8
- 235000013336 milk Nutrition 0.000 claims description 8
- 239000008267 milk Substances 0.000 claims description 8
- 210000004080 milk Anatomy 0.000 claims description 8
- 244000061520 Angelica archangelica Species 0.000 claims description 7
- 241000282994 Cervidae Species 0.000 claims description 7
- 235000001287 Guettarda speciosa Nutrition 0.000 claims description 7
- 241000235070 Saccharomyces Species 0.000 claims description 6
- 244000273928 Zingiber officinale Species 0.000 claims description 5
- 239000002245 particle Substances 0.000 claims description 4
- 238000010298 pulverizing process Methods 0.000 claims description 4
- 230000000694 effects Effects 0.000 abstract description 26
- 239000004615 ingredient Substances 0.000 abstract description 21
- 239000003814 drug Substances 0.000 abstract description 11
- 235000019658 bitter taste Nutrition 0.000 abstract description 10
- 238000003860 storage Methods 0.000 abstract description 3
- 244000001632 Acorus gramineus Species 0.000 abstract description 2
- 235000013073 Acorus gramineus Nutrition 0.000 abstract description 2
- 241001080798 Polygala tenuifolia Species 0.000 abstract description 2
- 241000951376 Schizonepeta tenuifolia Species 0.000 abstract description 2
- 244000057214 Stachys sieboldii Species 0.000 abstract description 2
- 235000005116 Stachys sieboldii Nutrition 0.000 abstract description 2
- 241000691199 Taraxacum platycarpum Species 0.000 abstract description 2
- 239000002131 composite material Substances 0.000 abstract description 2
- 239000000796 flavoring agent Substances 0.000 abstract description 2
- 235000019634 flavors Nutrition 0.000 abstract description 2
- 230000037406 food intake Effects 0.000 abstract description 2
- 241000271307 Aquilaria malaccensis Species 0.000 abstract 3
- 241001619454 Wolfiporia Species 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 235000013339 cereals Nutrition 0.000 description 22
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 22
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 19
- 239000004480 active ingredient Substances 0.000 description 17
- 241000402754 Erythranthe moschata Species 0.000 description 12
- 241000894006 Bacteria Species 0.000 description 11
- 235000000346 sugar Nutrition 0.000 description 11
- 238000000605 extraction Methods 0.000 description 10
- 238000010521 absorption reaction Methods 0.000 description 9
- 235000013305 food Nutrition 0.000 description 9
- 239000000203 mixture Substances 0.000 description 9
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 8
- 230000001965 increasing effect Effects 0.000 description 8
- 208000024827 Alzheimer disease Diseases 0.000 description 7
- 230000029087 digestion Effects 0.000 description 7
- 239000008213 purified water Substances 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- 230000003078 antioxidant effect Effects 0.000 description 6
- 230000036039 immunity Effects 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- 230000008569 process Effects 0.000 description 6
- 210000002784 stomach Anatomy 0.000 description 6
- 235000019640 taste Nutrition 0.000 description 6
- 240000004371 Panax ginseng Species 0.000 description 5
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 5
- 235000003140 Panax quinquefolius Nutrition 0.000 description 5
- 241000234314 Zingiber Species 0.000 description 5
- 230000001093 anti-cancer Effects 0.000 description 5
- 230000000259 anti-tumor effect Effects 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 230000017531 blood circulation Effects 0.000 description 5
- 238000009835 boiling Methods 0.000 description 5
- 230000000052 comparative effect Effects 0.000 description 5
- 206010012601 diabetes mellitus Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 235000013399 edible fruits Nutrition 0.000 description 5
- 230000002708 enhancing effect Effects 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 235000008434 ginseng Nutrition 0.000 description 5
- 230000012010 growth Effects 0.000 description 5
- 238000010438 heat treatment Methods 0.000 description 5
- 210000000936 intestine Anatomy 0.000 description 5
- 210000004185 liver Anatomy 0.000 description 5
- 230000028327 secretion Effects 0.000 description 5
- 230000001953 sensory effect Effects 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- DZOKWSREAZGFFC-XHDPSFHLSA-N (4ar,5s)-4a,5-dimethyl-3-propan-2-ylidene-5,6,7,8-tetrahydro-4h-naphthalen-2-one Chemical compound O=C1C(=C(C)C)C[C@]2(C)[C@@H](C)CCCC2=C1 DZOKWSREAZGFFC-XHDPSFHLSA-N 0.000 description 4
- 241001116389 Aloe Species 0.000 description 4
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 4
- 208000018737 Parkinson disease Diseases 0.000 description 4
- -1 Sekshon Chemical compound 0.000 description 4
- 230000009471 action Effects 0.000 description 4
- 235000011399 aloe vera Nutrition 0.000 description 4
- FAMPSKZZVDUYOS-UHFFFAOYSA-N alpha-Caryophyllene Natural products CC1=CCC(C)(C)C=CCC(C)=CCC1 FAMPSKZZVDUYOS-UHFFFAOYSA-N 0.000 description 4
- 230000003712 anti-aging effect Effects 0.000 description 4
- 230000003110 anti-inflammatory effect Effects 0.000 description 4
- 210000004556 brain Anatomy 0.000 description 4
- 239000011575 calcium Substances 0.000 description 4
- 229910052791 calcium Inorganic materials 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 230000006993 memory improvement Effects 0.000 description 4
- 235000015097 nutrients Nutrition 0.000 description 4
- 229940060184 oil ingredients Drugs 0.000 description 4
- 229940124595 oriental medicine Drugs 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 229960002181 saccharomyces boulardii Drugs 0.000 description 4
- 229940081969 saccharomyces cerevisiae Drugs 0.000 description 4
- 229930182490 saponin Natural products 0.000 description 4
- 150000007949 saponins Chemical class 0.000 description 4
- 235000017709 saponins Nutrition 0.000 description 4
- YEFOAORQXAOVJQ-RZFZLAGVSA-N schisandrol a Chemical group C1[C@H](C)[C@@](C)(O)CC2=CC(OC)=C(OC)C(OC)=C2C2=C1C=C(OC)C(OC)=C2OC YEFOAORQXAOVJQ-RZFZLAGVSA-N 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 230000000087 stabilizing effect Effects 0.000 description 4
- 230000001954 sterilising effect Effects 0.000 description 4
- 238000004659 sterilization and disinfection Methods 0.000 description 4
- 230000001256 tonic effect Effects 0.000 description 4
- NPNUFJAVOOONJE-ZIAGYGMSSA-N β-(E)-Caryophyllene Chemical compound C1CC(C)=CCCC(=C)[C@H]2CC(C)(C)[C@@H]21 NPNUFJAVOOONJE-ZIAGYGMSSA-N 0.000 description 4
- KWIUHFFTVRNATP-UHFFFAOYSA-N Betaine Natural products C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 206010020772 Hypertension Diseases 0.000 description 3
- KWIUHFFTVRNATP-UHFFFAOYSA-O N,N,N-trimethylglycinium Chemical compound C[N+](C)(C)CC(O)=O KWIUHFFTVRNATP-UHFFFAOYSA-O 0.000 description 3
- 206010029216 Nervousness Diseases 0.000 description 3
- 208000004880 Polyuria Diseases 0.000 description 3
- 208000006011 Stroke Diseases 0.000 description 3
- 230000000844 anti-bacterial effect Effects 0.000 description 3
- 230000037007 arousal Effects 0.000 description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 229960003237 betaine Drugs 0.000 description 3
- 230000036772 blood pressure Effects 0.000 description 3
- 235000012000 cholesterol Nutrition 0.000 description 3
- ZQSIJRDFPHDXIC-UHFFFAOYSA-N daidzein Chemical compound C1=CC(O)=CC=C1C1=COC2=CC(O)=CC=C2C1=O ZQSIJRDFPHDXIC-UHFFFAOYSA-N 0.000 description 3
- 230000035619 diuresis Effects 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 230000002964 excitative effect Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 230000002496 gastric effect Effects 0.000 description 3
- 230000003394 haemopoietic effect Effects 0.000 description 3
- 235000008216 herbs Nutrition 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 230000000968 intestinal effect Effects 0.000 description 3
- 206010027175 memory impairment Diseases 0.000 description 3
- 238000000465 moulding Methods 0.000 description 3
- 210000005036 nerve Anatomy 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- 230000003071 parasitic effect Effects 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 3
- 150000008163 sugars Chemical class 0.000 description 3
- 239000000341 volatile oil Substances 0.000 description 3
- XEEFSHTUESCNEP-ICNXTIMXSA-N (2r,3r,4s,5s,6r)-2-[[(2r,3s,4s,5r,6s)-6-[(2s)-2-[(3s,5r,6s,8r,9r,10r,12r,13r,14r,17s)-6-[(2r,3r,4s,5s,6r)-4,5-dihydroxy-6-(hydroxymethyl)-3-[(2s,3r,4s,5r)-3,4,5-trihydroxyoxan-2-yl]oxyoxan-2-yl]oxy-3,12-dihydroxy-4,4,8,10,14-pentamethyl-2,3,5,6,7,9,11,12, Chemical compound C([C@H]1O[C@H]([C@@H]([C@@H](O)[C@@H]1O)O)OC[C@H]1O[C@H]([C@@H]([C@@H](O)[C@@H]1O)O)O[C@@](C)(CCC=C(C)C)[C@@H]1[C@@H]2[C@@]([C@@]3(C[C@@H]([C@H]4C(C)(C)[C@@H](O)CC[C@]4(C)[C@H]3C[C@H]2O)O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O[C@H]2[C@@H]([C@@H](O)[C@H](O)CO2)O)C)(C)CC1)O[C@@H]1OC[C@@H](O)[C@H](O)[C@H]1O XEEFSHTUESCNEP-ICNXTIMXSA-N 0.000 description 2
- NVEQFIOZRFFVFW-UHFFFAOYSA-N 9-epi-beta-caryophyllene oxide Natural products C=C1CCC2OC2(C)CCC2C(C)(C)CC21 NVEQFIOZRFFVFW-UHFFFAOYSA-N 0.000 description 2
- 206010003210 Arteriosclerosis Diseases 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 208000028698 Cognitive impairment Diseases 0.000 description 2
- 208000004930 Fatty Liver Diseases 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 244000068988 Glycine max Species 0.000 description 2
- 235000010469 Glycine max Nutrition 0.000 description 2
- 206010019708 Hepatic steatosis Diseases 0.000 description 2
- 241000207923 Lamiaceae Species 0.000 description 2
- AMBQHHVBBHTQBF-UHFFFAOYSA-N Loganin Natural products C12C(C)C(O)CC2C(C(=O)OC)=COC1OC1OC(CO)C(O)C(O)C1O AMBQHHVBBHTQBF-UHFFFAOYSA-N 0.000 description 2
- IWDYQBDCEDNTDP-AOSWIFJRSA-N Notoginsenoside R4 Natural products O([C@](CC/C=C(\C)/C)(C)[C@@H]1[C@H]2[C@H](O)C[C@H]3[C@](C)([C@]2(C)CC1)CC[C@H]1C(C)(C)[C@@H](O[C@H]2[C@H](O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O4)[C@@H](O)[C@H](O)[C@@H](CO)O2)CC[C@]31C)[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]3[C@@H](O)[C@@H](O)[C@@H](O)CO3)O2)O1 IWDYQBDCEDNTDP-AOSWIFJRSA-N 0.000 description 2
- ZYEMGPIYFIJGTP-UHFFFAOYSA-N O-methyleugenol Chemical compound COC1=CC=C(CC=C)C=C1OC ZYEMGPIYFIJGTP-UHFFFAOYSA-N 0.000 description 2
- 240000007594 Oryza sativa Species 0.000 description 2
- 235000007164 Oryza sativa Nutrition 0.000 description 2
- 235000008331 Pinus X rigitaeda Nutrition 0.000 description 2
- 235000011613 Pinus brutia Nutrition 0.000 description 2
- 241000018646 Pinus brutia Species 0.000 description 2
- 244000184734 Pyrus japonica Species 0.000 description 2
- 241000235347 Schizosaccharomyces pombe Species 0.000 description 2
- 206010039966 Senile dementia Diseases 0.000 description 2
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 2
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 2
- 229960004373 acetylcholine Drugs 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 208000007502 anemia Diseases 0.000 description 2
- 230000000954 anitussive effect Effects 0.000 description 2
- 230000001773 anti-convulsant effect Effects 0.000 description 2
- 230000002929 anti-fatigue Effects 0.000 description 2
- 230000003579 anti-obesity Effects 0.000 description 2
- 230000002180 anti-stress Effects 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 229940124584 antitussives Drugs 0.000 description 2
- 208000011775 arteriosclerosis disease Diseases 0.000 description 2
- 206010003246 arthritis Diseases 0.000 description 2
- RKFAZBXYICVSKP-WAYWQWQTSA-N beta-asarone Chemical compound COC1=CC(OC)=C(\C=C/C)C=C1OC RKFAZBXYICVSKP-WAYWQWQTSA-N 0.000 description 2
- NPNUFJAVOOONJE-UHFFFAOYSA-N beta-cariophyllene Natural products C1CC(C)=CCCC(=C)C2CC(C)(C)C21 NPNUFJAVOOONJE-UHFFFAOYSA-N 0.000 description 2
- 235000013361 beverage Nutrition 0.000 description 2
- 210000004958 brain cell Anatomy 0.000 description 2
- 229940117948 caryophyllene Drugs 0.000 description 2
- NPNUFJAVOOONJE-UONOGXRCSA-N caryophyllene Natural products C1CC(C)=CCCC(=C)[C@@H]2CC(C)(C)[C@@H]21 NPNUFJAVOOONJE-UONOGXRCSA-N 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 208000026106 cerebrovascular disease Diseases 0.000 description 2
- 230000004087 circulation Effects 0.000 description 2
- 208000010877 cognitive disease Diseases 0.000 description 2
- DZOKWSREAZGFFC-UHFFFAOYSA-N dehydrofukinone Natural products O=C1C(=C(C)C)CC2(C)C(C)CCCC2=C1 DZOKWSREAZGFFC-UHFFFAOYSA-N 0.000 description 2
- 230000001079 digestive effect Effects 0.000 description 2
- ZZVUWRFHKOJYTH-UHFFFAOYSA-N diphenhydramine Chemical compound C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 ZZVUWRFHKOJYTH-UHFFFAOYSA-N 0.000 description 2
- 201000006549 dyspepsia Diseases 0.000 description 2
- RRAFCDWBNXTKKO-UHFFFAOYSA-N eugenol Chemical compound COC1=CC(CC=C)=CC=C1O RRAFCDWBNXTKKO-UHFFFAOYSA-N 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 230000008020 evaporation Effects 0.000 description 2
- 230000003419 expectorant effect Effects 0.000 description 2
- 208000010706 fatty liver disease Diseases 0.000 description 2
- 229930003935 flavonoid Natural products 0.000 description 2
- 235000017173 flavonoids Nutrition 0.000 description 2
- 150000002215 flavonoids Chemical class 0.000 description 2
- FTSSQIKWUOOEGC-RULYVFMPSA-N fructooligosaccharide Chemical compound OC[C@H]1O[C@@](CO)(OC[C@@]2(OC[C@@]3(OC[C@@]4(OC[C@@]5(OC[C@@]6(OC[C@@]7(OC[C@@]8(OC[C@@]9(OC[C@@]%10(OC[C@@]%11(O[C@H]%12O[C@H](CO)[C@@H](O)[C@H](O)[C@H]%12O)O[C@H](CO)[C@@H](O)[C@@H]%11O)O[C@H](CO)[C@@H](O)[C@@H]%10O)O[C@H](CO)[C@@H](O)[C@@H]9O)O[C@H](CO)[C@@H](O)[C@@H]8O)O[C@H](CO)[C@@H](O)[C@@H]7O)O[C@H](CO)[C@@H](O)[C@@H]6O)O[C@H](CO)[C@@H](O)[C@@H]5O)O[C@H](CO)[C@@H](O)[C@@H]4O)O[C@H](CO)[C@@H](O)[C@@H]3O)O[C@H](CO)[C@@H](O)[C@@H]2O)[C@@H](O)[C@@H]1O FTSSQIKWUOOEGC-RULYVFMPSA-N 0.000 description 2
- 229940107187 fructooligosaccharide Drugs 0.000 description 2
- 210000004051 gastric juice Anatomy 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 229930182470 glycoside Natural products 0.000 description 2
- 150000002338 glycosides Chemical class 0.000 description 2
- ZWRRJEICIPUPHZ-MYODQAERSA-N gomisin a Chemical compound COC1=C2C=3C(OC)=C(OC)C(OC)=CC=3C[C@](C)(O)[C@@H](C)CC2=CC2=C1OCO2 ZWRRJEICIPUPHZ-MYODQAERSA-N 0.000 description 2
- 238000000227 grinding Methods 0.000 description 2
- 239000012676 herbal extract Substances 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- XMGQYMWWDOXHJM-UHFFFAOYSA-N limonene Chemical compound CC(=C)C1CCC(C)=CC1 XMGQYMWWDOXHJM-UHFFFAOYSA-N 0.000 description 2
- AMBQHHVBBHTQBF-UOUCRYGSSA-N loganin Chemical compound O([C@@H]1OC=C([C@H]2C[C@H](O)[C@H](C)[C@H]21)C(=O)OC)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O AMBQHHVBBHTQBF-UOUCRYGSSA-N 0.000 description 2
- 230000007721 medicinal effect Effects 0.000 description 2
- 230000006996 mental state Effects 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 239000002858 neurotransmitter agent Substances 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- KFUCYPGCMLPUMT-UHFFFAOYSA-N perlolyrine Chemical compound O1C(CO)=CC=C1C1=NC=CC2=C1NC1=CC=CC=C21 KFUCYPGCMLPUMT-UHFFFAOYSA-N 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 230000003449 preventive effect Effects 0.000 description 2
- 239000011347 resin Substances 0.000 description 2
- 229920005989 resin Polymers 0.000 description 2
- SGAWOGXMMPSZPB-UHFFFAOYSA-N safranal Chemical compound CC1=C(C=O)C(C)(C)CC=C1 SGAWOGXMMPSZPB-UHFFFAOYSA-N 0.000 description 2
- 229930193195 schizandrin Natural products 0.000 description 2
- RODXRVNMMDRFIK-UHFFFAOYSA-N scopoletin Chemical compound C1=CC(=O)OC2=C1C=C(OC)C(O)=C2 RODXRVNMMDRFIK-UHFFFAOYSA-N 0.000 description 2
- 235000019654 spicy taste Nutrition 0.000 description 2
- 231100000240 steatosis hepatitis Toxicity 0.000 description 2
- 208000023516 stroke disease Diseases 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- YEFOAORQXAOVJQ-UHFFFAOYSA-N wuweizischun A Natural products C1C(C)C(C)(O)CC2=CC(OC)=C(OC)C(OC)=C2C2=C1C=C(OC)C(OC)=C2OC YEFOAORQXAOVJQ-UHFFFAOYSA-N 0.000 description 2
- JNELGWHKGNBSMD-UHFFFAOYSA-N xanthone Chemical compound C1=CC=C2C(=O)C3=CC=CC=C3OC2=C1 JNELGWHKGNBSMD-UHFFFAOYSA-N 0.000 description 2
- PSQYTAPXSHCGMF-BQYQJAHWSA-N β-ionone Chemical compound CC(=O)\C=C\C1=C(C)CCCC1(C)C PSQYTAPXSHCGMF-BQYQJAHWSA-N 0.000 description 2
- SFEOKXHPFMOVRM-UHFFFAOYSA-N (+)-(S)-gamma-ionone Natural products CC(=O)C=CC1C(=C)CCCC1(C)C SFEOKXHPFMOVRM-UHFFFAOYSA-N 0.000 description 1
- 239000001100 (2S)-5,7-dihydroxy-2-(3-hydroxy-4-methoxyphenyl)chroman-4-one Substances 0.000 description 1
- JSPNNZKWADNWHI-PNANGNLXSA-N (2r)-2-hydroxy-n-[(2s,3r,4e,8e)-3-hydroxy-9-methyl-1-[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoctadeca-4,8-dien-2-yl]heptadecanamide Chemical compound CCCCCCCCCCCCCCC[C@@H](O)C(=O)N[C@H]([C@H](O)\C=C\CC\C=C(/C)CCCCCCCCC)CO[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O JSPNNZKWADNWHI-PNANGNLXSA-N 0.000 description 1
- JKQXZKUSFCKOGQ-JLGXGRJMSA-N (3R,3'R)-beta,beta-carotene-3,3'-diol Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)C[C@@H](O)CC1(C)C JKQXZKUSFCKOGQ-JLGXGRJMSA-N 0.000 description 1
- UVDMQKFZJPSOJT-UHFFFAOYSA-N 1-methyl-3,4-dihydropyrido[3,4-b]indole-9-carbaldehyde Chemical compound C(=O)N1C2=CC=CC=C2C=2CCN=C(C)C1=2 UVDMQKFZJPSOJT-UHFFFAOYSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- NFZYDZXHKFHPGA-UHFFFAOYSA-N 17alpha-hydroxygofruside Natural products C12CC(C)(C)CCC2(C(=O)OC2C(C(O)C(O)C(CO)O2)O)CCC(C2(CCC3C4(C)C)C)(C)C1=CCC2C3(C)CCC4OC1OC(C(O)=O)C(O)C(O)C1OC1OC(CO)C(O)C(O)C1O NFZYDZXHKFHPGA-UHFFFAOYSA-N 0.000 description 1
- HFRZSVYKDDZRQY-AATRIKPKSA-N 3-Hydroxy-beta-ionone Chemical compound CC(=O)\C=C\C1=C(C)CC(O)CC1(C)C HFRZSVYKDDZRQY-AATRIKPKSA-N 0.000 description 1
- LICNQDPDQQOXCU-FYJFLYSWSA-N 3-Hydroxy-beta-ionone Natural products CC(=O)\C=C\C1=C(C)[C@@H](O)CCC1(C)C LICNQDPDQQOXCU-FYJFLYSWSA-N 0.000 description 1
- PUQSUZTXKPLAPR-KSSYENDESA-N 4-(beta-D-Glucopyranosyloxy) benzyl alcohol Natural products O([C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1)c1ccc(CO)cc1 PUQSUZTXKPLAPR-KSSYENDESA-N 0.000 description 1
- 239000001606 7-[(2S,3R,4S,5S,6R)-4,5-dihydroxy-6-(hydroxymethyl)-3-[(2S,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxyoxan-2-yl]oxy-5-hydroxy-2-(4-hydroxyphenyl)chroman-4-one Substances 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 206010000087 Abdominal pain upper Diseases 0.000 description 1
- 241000332371 Abutilon x hybridum Species 0.000 description 1
- ICWHTQRTTHCUHW-NFAWXSAZSA-N Agarospirol Chemical compound C[C@@H]1CCC=C(C)[C@]11C[C@H](C(C)(C)O)CC1 ICWHTQRTTHCUHW-NFAWXSAZSA-N 0.000 description 1
- ICWHTQRTTHCUHW-UHFFFAOYSA-N Agarospirol Natural products CC1CCC=C(C)C11CC(C(C)(C)O)CC1 ICWHTQRTTHCUHW-UHFFFAOYSA-N 0.000 description 1
- 241000271309 Aquilaria crassna Species 0.000 description 1
- 244000221226 Armillaria mellea Species 0.000 description 1
- 235000011569 Armillaria mellea Nutrition 0.000 description 1
- 241001061264 Astragalus Species 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 241000193738 Bacillus anthracis Species 0.000 description 1
- 241000221198 Basidiomycota Species 0.000 description 1
- 208000014644 Brain disease Diseases 0.000 description 1
- 206010006458 Bronchitis chronic Diseases 0.000 description 1
- 241000282461 Canis lupus Species 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 244000201986 Cassia tora Species 0.000 description 1
- 235000014552 Cassia tora Nutrition 0.000 description 1
- NPBVQXIMTZKSBA-UHFFFAOYSA-N Chavibetol Natural products COC1=CC=C(CC=C)C=C1O NPBVQXIMTZKSBA-UHFFFAOYSA-N 0.000 description 1
- NFZYDZXHKFHPGA-QQHDHSITSA-N Chikusetsusaponin-V Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@H]1O[C@H]1CC[C@]2(C)[C@H]3CC=C4[C@@]([C@@]3(CC[C@H]2C1(C)C)C)(C)CC[C@]1(CCC(C[C@H]14)(C)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)C(O)=O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O NFZYDZXHKFHPGA-QQHDHSITSA-N 0.000 description 1
- 241000548268 Citrus deliciosa Species 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 241000190633 Cordyceps Species 0.000 description 1
- 241000142975 Cornaceae Species 0.000 description 1
- 235000017788 Cydonia oblonga Nutrition 0.000 description 1
- 108010001202 Cytochrome P-450 CYP2E1 Proteins 0.000 description 1
- 102100024889 Cytochrome P450 2E1 Human genes 0.000 description 1
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 1
- GMTUGPYJRUMVTC-UHFFFAOYSA-N Daidzin Natural products OC(COc1ccc2C(=O)C(=COc2c1)c3ccc(O)cc3)C(O)C(O)C(O)C=O GMTUGPYJRUMVTC-UHFFFAOYSA-N 0.000 description 1
- KYQZWONCHDNPDP-UHFFFAOYSA-N Daidzoside Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C2C(=O)C(C=3C=CC(O)=CC=3)=COC2=C1 KYQZWONCHDNPDP-UHFFFAOYSA-N 0.000 description 1
- 206010012438 Dermatitis atopic Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- XEHFSYYAGCUKEN-UHFFFAOYSA-N Dihydroscopoletin Natural products C1CC(=O)OC2=C1C=C(OC)C(O)=C2 XEHFSYYAGCUKEN-UHFFFAOYSA-N 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 239000005770 Eugenol Substances 0.000 description 1
- 102000012673 Follicle Stimulating Hormone Human genes 0.000 description 1
- 108010079345 Follicle Stimulating Hormone Proteins 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 206010017711 Gangrene Diseases 0.000 description 1
- 208000007882 Gastritis Diseases 0.000 description 1
- PUQSUZTXKPLAPR-UJPOAAIJSA-N Gastrodin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=C(CO)C=C1 PUQSUZTXKPLAPR-UJPOAAIJSA-N 0.000 description 1
- 229920002683 Glycosaminoglycan Polymers 0.000 description 1
- 239000009691 Gongjin-dan Substances 0.000 description 1
- 240000002045 Guettarda speciosa Species 0.000 description 1
- 241000590002 Helicobacter pylori Species 0.000 description 1
- QUQPHWDTPGMPEX-UHFFFAOYSA-N Hesperidine Natural products C1=C(O)C(OC)=CC=C1C1OC2=CC(OC3C(C(O)C(O)C(COC4C(C(O)C(O)C(C)O4)O)O3)O)=CC(O)=C2C(=O)C1 QUQPHWDTPGMPEX-UHFFFAOYSA-N 0.000 description 1
- 208000023105 Huntington disease Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010022489 Insulin Resistance Diseases 0.000 description 1
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 1
- 206010023126 Jaundice Diseases 0.000 description 1
- 241000721662 Juniperus Species 0.000 description 1
- 208000009829 Lewy Body Disease Diseases 0.000 description 1
- 201000002832 Lewy body dementia Diseases 0.000 description 1
- 206010067125 Liver injury Diseases 0.000 description 1
- 102000009151 Luteinizing Hormone Human genes 0.000 description 1
- 108010073521 Luteinizing Hormone Proteins 0.000 description 1
- UPYKUZBSLRQECL-UKMVMLAPSA-N Lycopene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1C(=C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=C)CCCC2(C)C UPYKUZBSLRQECL-UKMVMLAPSA-N 0.000 description 1
- 208000007466 Male Infertility Diseases 0.000 description 1
- 235000010804 Maranta arundinacea Nutrition 0.000 description 1
- YKVWPZJHENXDAJ-VOTSOKGWSA-N Megastigmatrienone Chemical compound CC1=CC(=O)CC(C)(C)C1\C=C\C=C YKVWPZJHENXDAJ-VOTSOKGWSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241001416180 Moschidae Species 0.000 description 1
- 235000003805 Musa ABB Group Nutrition 0.000 description 1
- 240000005561 Musa balbisiana Species 0.000 description 1
- 241000187479 Mycobacterium tuberculosis Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- QRCQKHQZVXXKQT-UHFFFAOYSA-N OCC1=CC=C(C=O)O1.OCC=1C=COC=1C=O Chemical compound OCC1=CC=C(C=O)O1.OCC=1C=COC=1C=O QRCQKHQZVXXKQT-UHFFFAOYSA-N 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 241000233855 Orchidaceae Species 0.000 description 1
- 235000007189 Oryza longistaminata Nutrition 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 206010033557 Palpitations Diseases 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 244000062780 Petroselinum sativum Species 0.000 description 1
- 244000046052 Phaseolus vulgaris Species 0.000 description 1
- 235000010627 Phaseolus vulgaris Nutrition 0.000 description 1
- XACHQDDXHDTRLX-XLVVAOPESA-N Physalien Chemical compound CC1(C)C[C@H](OC(=O)CCCCCCCCCCCCCCC)CC(C)=C1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)C[C@@H](OC(=O)CCCCCCCCCCCCCCC)CC1(C)C XACHQDDXHDTRLX-XLVVAOPESA-N 0.000 description 1
- XACHQDDXHDTRLX-GMPBGBGESA-N Physalien Natural products O=C(O[C@H]1CC(C)(C)C(/C=C/C(=C\C=C\C(=C/C=C/C=C(\C=C\C=C(/C=C/C=2C(C)(C)C[C@H](OC(=O)CCCCCCCCCCCCCCC)CC=2C)\C)/C)\C)/C)=C(C)C1)CCCCCCCCCCCCCCC XACHQDDXHDTRLX-GMPBGBGESA-N 0.000 description 1
- 235000015266 Plantago major Nutrition 0.000 description 1
- 108010020346 Polyglutamic Acid Proteins 0.000 description 1
- 244000197580 Poria cocos Species 0.000 description 1
- 235000008599 Poria cocos Nutrition 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- UVMRYBDEERADNV-UHFFFAOYSA-N Pseudoeugenol Natural products COC1=CC(C(C)=C)=CC=C1O UVMRYBDEERADNV-UHFFFAOYSA-N 0.000 description 1
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 1
- RXUWDKBZZLIASQ-UHFFFAOYSA-N Puerarin Natural products OCC1OC(Oc2c(O)cc(O)c3C(=O)C(=COc23)c4ccc(O)cc4)C(O)C(O)C1O RXUWDKBZZLIASQ-UHFFFAOYSA-N 0.000 description 1
- MUPFEKGTMRGPLJ-RMMQSMQOSA-N Raffinose Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@@H](O)[C@@H](CO)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 MUPFEKGTMRGPLJ-RMMQSMQOSA-N 0.000 description 1
- 241000405414 Rehmannia Species 0.000 description 1
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 1
- 241000576755 Sclerotia Species 0.000 description 1
- 206010039897 Sedation Diseases 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 244000061456 Solanum tuberosum Species 0.000 description 1
- 235000002595 Solanum tuberosum Nutrition 0.000 description 1
- 102000013275 Somatomedins Human genes 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 208000007107 Stomach Ulcer Diseases 0.000 description 1
- VSJGJMKGNMDJCI-ZASXJUAOSA-N Sweroside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@H]1[C@H](C=C)[C@H](CCOC2=O)C2=CO1 VSJGJMKGNMDJCI-ZASXJUAOSA-N 0.000 description 1
- 241000245665 Taraxacum Species 0.000 description 1
- 235000005187 Taraxacum officinale ssp. officinale Nutrition 0.000 description 1
- 244000145580 Thalia geniculata Species 0.000 description 1
- 235000012419 Thalia geniculata Nutrition 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- 244000098338 Triticum aestivum Species 0.000 description 1
- MUPFEKGTMRGPLJ-UHFFFAOYSA-N UNPD196149 Natural products OC1C(O)C(CO)OC1(CO)OC1C(O)C(O)C(O)C(COC2C(C(O)C(O)C(CO)O2)O)O1 MUPFEKGTMRGPLJ-UHFFFAOYSA-N 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 201000004810 Vascular dementia Diseases 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 229930003270 Vitamin B Natural products 0.000 description 1
- 229930003451 Vitamin B1 Natural products 0.000 description 1
- 229930003471 Vitamin B2 Natural products 0.000 description 1
- JKQXZKUSFCKOGQ-LQFQNGICSA-N Z-zeaxanthin Natural products C([C@H](O)CC=1C)C(C)(C)C=1C=CC(C)=CC=CC(C)=CC=CC=C(C)C=CC=C(C)C=CC1=C(C)C[C@@H](O)CC1(C)C JKQXZKUSFCKOGQ-LQFQNGICSA-N 0.000 description 1
- QOPRSMDTRDMBNK-RNUUUQFGSA-N Zeaxanthin Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCC(O)C1(C)C)C=CC=C(/C)C=CC2=C(C)CC(O)CC2(C)C QOPRSMDTRDMBNK-RNUUUQFGSA-N 0.000 description 1
- XACHQDDXHDTRLX-UHFFFAOYSA-N Zeaxanthin-dipalmitat Natural products CC1(C)CC(OC(=O)CCCCCCCCCCCCCCC)CC(C)=C1C=CC(C)=CC=CC(C)=CC=CC=C(C)C=CC=C(C)C=CC1=C(C)CC(OC(=O)CCCCCCCCCCCCCCC)CC1(C)C XACHQDDXHDTRLX-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000016571 aggressive behavior Effects 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- JKQXZKUSFCKOGQ-LOFNIBRQSA-N all-trans-Zeaxanthin Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2=C(C)CC(O)CC2(C)C JKQXZKUSFCKOGQ-LOFNIBRQSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- LHAOFBCHXGZGOR-NAVBLJQLSA-N alpha-D-Manp-(1->3)-alpha-D-Manp-(1->2)-alpha-D-Manp Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@@H](O[C@@H]2[C@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)[C@H](O)[C@@H](CO)O1 LHAOFBCHXGZGOR-NAVBLJQLSA-N 0.000 description 1
- WUOACPNHFRMFPN-UHFFFAOYSA-N alpha-terpineol Chemical compound CC1=CCC(C(C)(C)O)CC1 WUOACPNHFRMFPN-UHFFFAOYSA-N 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- 230000003178 anti-diabetic effect Effects 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 230000001754 anti-pyretic effect Effects 0.000 description 1
- 230000002785 anti-thrombosis Effects 0.000 description 1
- 230000000767 anti-ulcer Effects 0.000 description 1
- 230000001153 anti-wrinkle effect Effects 0.000 description 1
- 239000001961 anticonvulsive agent Substances 0.000 description 1
- 229960003965 antiepileptics Drugs 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 229940030225 antihemorrhagics Drugs 0.000 description 1
- 239000002221 antipyretic Substances 0.000 description 1
- 229940125716 antipyretic agent Drugs 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 235000006533 astragalus Nutrition 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- QUQPHWDTPGMPEX-UTWYECKDSA-N aurantiamarin Natural products COc1ccc(cc1O)[C@H]1CC(=O)c2c(O)cc(O[C@@H]3O[C@H](CO[C@@H]4O[C@@H](C)[C@H](O)[C@@H](O)[C@H]4O)[C@@H](O)[C@H](O)[C@H]3O)cc2O1 QUQPHWDTPGMPEX-UTWYECKDSA-N 0.000 description 1
- 238000003287 bathing Methods 0.000 description 1
- 229940076810 beta sitosterol Drugs 0.000 description 1
- RKFAZBXYICVSKP-UHFFFAOYSA-N beta- asarone Natural products COC1=CC(OC)=C(C=CC)C=C1OC RKFAZBXYICVSKP-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 description 1
- LGJMUZUPVCAVPU-UHFFFAOYSA-N beta-Sitostanol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(CC)C(C)C)C1(C)CC2 LGJMUZUPVCAVPU-UHFFFAOYSA-N 0.000 description 1
- NJKOMDUNNDKEAI-UHFFFAOYSA-N beta-sitosterol Natural products CCC(CCC(C)C1CCC2(C)C3CC=C4CC(O)CCC4C3CCC12C)C(C)C NJKOMDUNNDKEAI-UHFFFAOYSA-N 0.000 description 1
- 230000004531 blood pressure lowering effect Effects 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 230000006931 brain damage Effects 0.000 description 1
- 231100000874 brain damage Toxicity 0.000 description 1
- 230000003925 brain function Effects 0.000 description 1
- 208000029028 brain injury Diseases 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 230000003182 bronchodilatating effect Effects 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 150000001746 carotenes Chemical class 0.000 description 1
- 235000005473 carotenes Nutrition 0.000 description 1
- 235000021466 carotenoid Nutrition 0.000 description 1
- 150000001747 carotenoids Chemical class 0.000 description 1
- LHDWRKICQLTVDL-PZYDOOQISA-N catalpol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@H]1[C@@H]2[C@@]3(CO)O[C@H]3[C@@H](O)[C@@H]2C=CO1 LHDWRKICQLTVDL-PZYDOOQISA-N 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 229930183167 cerebroside Natural products 0.000 description 1
- RIZIAUKTHDLMQX-UHFFFAOYSA-N cerebroside D Natural products CCCCCCCCCCCCCCCCC(O)C(=O)NC(C(O)C=CCCC=C(C)CCCCCCCCC)COC1OC(CO)C(O)C(O)C1O RIZIAUKTHDLMQX-UHFFFAOYSA-N 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 208000007451 chronic bronchitis Diseases 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- APSNPMVGBGZYAJ-GLOOOPAXSA-N clematine Natural products COc1cc(ccc1O)[C@@H]2CC(=O)c3c(O)cc(O[C@@H]4O[C@H](CO[C@H]5O[C@@H](C)[C@H](O)[C@@H](O)[C@H]5O)[C@@H](O)[C@H](O)[C@H]4O)cc3O2 APSNPMVGBGZYAJ-GLOOOPAXSA-N 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 230000019771 cognition Effects 0.000 description 1
- 230000003930 cognitive ability Effects 0.000 description 1
- 230000037410 cognitive enhancement Effects 0.000 description 1
- 230000003920 cognitive function Effects 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- KUFXJZXMWHNCEH-UHFFFAOYSA-N cyperone Natural products C1CC(=O)C(C)=C2CC(C(=C)C)CCC21C KUFXJZXMWHNCEH-UHFFFAOYSA-N 0.000 description 1
- 235000007240 daidzein Nutrition 0.000 description 1
- KYQZWONCHDNPDP-QNDFHXLGSA-N daidzein 7-O-beta-D-glucoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=C2C(=O)C(C=3C=CC(O)=CC=3)=COC2=C1 KYQZWONCHDNPDP-QNDFHXLGSA-N 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000003412 degenerative effect Effects 0.000 description 1
- SQIFACVGCPWBQZ-UHFFFAOYSA-N delta-terpineol Natural products CC(C)(O)C1CCC(=C)CC1 SQIFACVGCPWBQZ-UHFFFAOYSA-N 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 229940124568 digestive agent Drugs 0.000 description 1
- 210000002249 digestive system Anatomy 0.000 description 1
- 206010013023 diphtheria Diseases 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 208000001848 dysentery Diseases 0.000 description 1
- 210000005069 ears Anatomy 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 229960002217 eugenol Drugs 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 239000003172 expectorant agent Substances 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 239000010685 fatty oil Substances 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 229940028334 follicle stimulating hormone Drugs 0.000 description 1
- BXWQUXUDAGDUOS-UHFFFAOYSA-N gamma-humulene Natural products CC1=CCCC(C)(C)C=CC(=C)CCC1 BXWQUXUDAGDUOS-UHFFFAOYSA-N 0.000 description 1
- 201000005917 gastric ulcer Diseases 0.000 description 1
- 229930193974 gastrodin Natural products 0.000 description 1
- 235000006539 genistein Nutrition 0.000 description 1
- TZBJGXHYKVUXJN-UHFFFAOYSA-N genistein Natural products C1=CC(O)=CC=C1C1=COC2=CC(O)=CC(O)=C2C1=O TZBJGXHYKVUXJN-UHFFFAOYSA-N 0.000 description 1
- 229940045109 genistein Drugs 0.000 description 1
- ZCOLJUOHXJRHDI-CMWLGVBASA-N genistein 7-O-beta-D-glucoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=C2C(=O)C(C=3C=CC(O)=CC=3)=COC2=C1 ZCOLJUOHXJRHDI-CMWLGVBASA-N 0.000 description 1
- KVMXBSSOCCPAOR-UHFFFAOYSA-N ginsenoside ra1 Chemical compound C1CC(C2(CCC3C(C)(C)C(OC4C(C(O)C(O)C(CO)O4)OC4C(C(O)C(O)C(CO)O4)O)CCC3(C)C2CC2O)C)(C)C2C1C(C)(CCC=C(C)C)OC(C(C(O)C1O)O)OC1COC(C(C1O)O)OCC1OC1OCC(O)C(O)C1O KVMXBSSOCCPAOR-UHFFFAOYSA-N 0.000 description 1
- YLOTVUIQEWTDME-UHFFFAOYSA-N ginsenoside-Ra1 Natural products CC(=CCCC(C)(OC1OC(COC2OCC(OC3OCC(O)C(O)C3O)C(O)C2O)C(O)C(O)C1O)C4CCC5(C)C4C(O)CC6C7(C)CCC(OC8C(O)C(O)C(CO)OC8OC9OC(CO)C(O)C(O)C9O)C(C)(C)C7CCC56C)C YLOTVUIQEWTDME-UHFFFAOYSA-N 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000010247 heart contraction Effects 0.000 description 1
- PUQSUZTXKPLAPR-NZEXEKPDSA-N helicidol Natural products O([C@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](CO)O1)c1ccc(CO)cc1 PUQSUZTXKPLAPR-NZEXEKPDSA-N 0.000 description 1
- 229940037467 helicobacter pylori Drugs 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 239000002874 hemostatic agent Substances 0.000 description 1
- 230000002439 hemostatic effect Effects 0.000 description 1
- 231100000234 hepatic damage Toxicity 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 230000002443 hepatoprotective effect Effects 0.000 description 1
- 229940025878 hesperidin Drugs 0.000 description 1
- VUYDGVRIQRPHFX-UHFFFAOYSA-N hesperidin Natural products COc1cc(ccc1O)C2CC(=O)c3c(O)cc(OC4OC(COC5OC(O)C(O)C(O)C5O)C(O)C(O)C4O)cc3O2 VUYDGVRIQRPHFX-UHFFFAOYSA-N 0.000 description 1
- QUQPHWDTPGMPEX-QJBIFVCTSA-N hesperidin Chemical compound C1=C(O)C(OC)=CC=C1[C@H]1OC2=CC(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO[C@H]4[C@@H]([C@H](O)[C@@H](O)[C@H](C)O4)O)O3)O)=CC(O)=C2C(=O)C1 QUQPHWDTPGMPEX-QJBIFVCTSA-N 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- QBNFBHXQESNSNP-UHFFFAOYSA-N humulene Natural products CC1=CC=CC(C)(C)CC=C(/C)CCC1 QBNFBHXQESNSNP-UHFFFAOYSA-N 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 230000005965 immune activity Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 230000004941 influx Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 229930182489 iridoid glycoside Natural products 0.000 description 1
- 150000008145 iridoid glycosides Chemical class 0.000 description 1
- GOMNOOKGLZYEJT-UHFFFAOYSA-N isoflavone Chemical compound C=1OC2=CC=CC=C2C(=O)C=1C1=CC=CC=C1 GOMNOOKGLZYEJT-UHFFFAOYSA-N 0.000 description 1
- CJWQYWQDLBZGPD-UHFFFAOYSA-N isoflavone Natural products C1=C(OC)C(OC)=CC(OC)=C1C1=COC2=C(C=CC(C)(C)O3)C3=C(OC)C=C2C1=O CJWQYWQDLBZGPD-UHFFFAOYSA-N 0.000 description 1
- 235000008696 isoflavones Nutrition 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000003292 kidney cell Anatomy 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 235000001510 limonene Nutrition 0.000 description 1
- 229940087305 limonene Drugs 0.000 description 1
- 150000002630 limonoids Chemical class 0.000 description 1
- 230000008818 liver damage Effects 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 229940040129 luteinizing hormone Drugs 0.000 description 1
- 239000002075 main ingredient Substances 0.000 description 1
- FYGDTMLNYKFZSV-UHFFFAOYSA-N mannotriose Natural products OC1C(O)C(O)C(CO)OC1OC1C(CO)OC(OC2C(OC(O)C(O)C2O)CO)C(O)C1O FYGDTMLNYKFZSV-UHFFFAOYSA-N 0.000 description 1
- 238000000691 measurement method Methods 0.000 description 1
- 230000007087 memory ability Effects 0.000 description 1
- 230000006386 memory function Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- FRNCTTUBAHKEBZ-UHFFFAOYSA-N methyl 9h-pyrido[3,4-b]indole-1-carboxylate Chemical compound C12=CC=CC=C2NC2=C1C=CN=C2C(=O)OC FRNCTTUBAHKEBZ-UHFFFAOYSA-N 0.000 description 1
- LHDWRKICQLTVDL-UHFFFAOYSA-N methyl iridoid glycoside Natural products OC1C(O)C(O)C(CO)OC1OC1C2C3(CO)OC3C(O)C2C=CO1 LHDWRKICQLTVDL-UHFFFAOYSA-N 0.000 description 1
- 229940116837 methyleugenol Drugs 0.000 description 1
- PRHTXAOWJQTLBO-UHFFFAOYSA-N methyleugenol Natural products COC1=CC=C(C(C)=C)C=C1OC PRHTXAOWJQTLBO-UHFFFAOYSA-N 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 239000011812 mixed powder Substances 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 229930019673 naringin Natural products 0.000 description 1
- DFPMSGMNTNDNHN-ZPHOTFPESA-N naringin Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@H]1[C@H](OC=2C=C3O[C@@H](CC(=O)C3=C(O)C=2)C=2C=CC(O)=CC=2)O[C@H](CO)[C@@H](O)[C@@H]1O DFPMSGMNTNDNHN-ZPHOTFPESA-N 0.000 description 1
- 229940052490 naringin Drugs 0.000 description 1
- 229940086319 nattokinase Drugs 0.000 description 1
- 108010073682 nattokinase Proteins 0.000 description 1
- ARGKVCXINMKCAZ-UHFFFAOYSA-N neohesperidine Natural products C1=C(O)C(OC)=CC=C1C1OC2=CC(OC3C(C(O)C(O)C(CO)O3)OC3C(C(O)C(O)C(C)O3)O)=CC(O)=C2C(=O)C1 ARGKVCXINMKCAZ-UHFFFAOYSA-N 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 208000004296 neuralgia Diseases 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 239000003129 oil well Substances 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 235000011197 perejil Nutrition 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- GWBIYORWNUYYMZ-UHFFFAOYSA-N platycodin D Natural products CC1OC(OC2C(O)C(O)COC2OC(=O)C34CCC(C)(C)CC3C5=CCC6C7(C)CC(O)C(OC8CC(CO)C(O)C(O)C8O)C(CO)(CO)C7CCC6(C)C5(C)CC4O)C(O)C(O)C1OC9OCC(O)C(OC%10OCC(O)(CO)C%10O)C9O GWBIYORWNUYYMZ-UHFFFAOYSA-N 0.000 description 1
- CYBWUNOAQPMRBA-NDTOZIJESA-N platycodin D Chemical compound O([C@H]1[C@@H](O)C[C@]2(C)[C@H]3CC=C4[C@@H]5CC(C)(C)CC[C@@]5([C@@H](C[C@@]4(C)[C@]3(C)CC[C@H]2C1(CO)CO)O)C(=O)O[C@@H]1OC[C@H](O)[C@H](O)[C@H]1O[C@@H]1O[C@H]([C@@H]([C@@H](O)[C@H]1O)O[C@H]1[C@@H]([C@@H](O[C@H]2[C@@H]([C@@](O)(CO)CO2)O)[C@H](O)CO1)O)C)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O CYBWUNOAQPMRBA-NDTOZIJESA-N 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 229920002643 polyglutamic acid Polymers 0.000 description 1
- 235000012015 potatoes Nutrition 0.000 description 1
- 239000000955 prescription drug Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- HKEAFJYKMMKDOR-VPRICQMDSA-N puerarin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1C1=C(O)C=CC(C2=O)=C1OC=C2C1=CC=C(O)C=C1 HKEAFJYKMMKDOR-VPRICQMDSA-N 0.000 description 1
- 208000008128 pulmonary tuberculosis Diseases 0.000 description 1
- 238000004537 pulping Methods 0.000 description 1
- 150000003233 pyrroles Chemical class 0.000 description 1
- 150000003248 quinolines Chemical class 0.000 description 1
- HFRZSVYKDDZRQY-UHFFFAOYSA-N rac-3-Hydroxy-beta-ionone Natural products CC(=O)C=CC1=C(C)CC(O)CC1(C)C HFRZSVYKDDZRQY-UHFFFAOYSA-N 0.000 description 1
- MUPFEKGTMRGPLJ-ZQSKZDJDSA-N raffinose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)O1 MUPFEKGTMRGPLJ-ZQSKZDJDSA-N 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000004648 relaxation of smooth muscle Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 229960002477 riboflavin Drugs 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 239000011435 rock Substances 0.000 description 1
- 235000017509 safranal Nutrition 0.000 description 1
- ZWRRJEICIPUPHZ-UHFFFAOYSA-N schisandrol B Natural products COC1=C2C=3C(OC)=C(OC)C(OC)=CC=3CC(C)(O)C(C)CC2=CC2=C1OCO2 ZWRRJEICIPUPHZ-UHFFFAOYSA-N 0.000 description 1
- FWYIBGHGBOVPNL-UHFFFAOYSA-N scopoletin Natural products COC=1C=C2C=CC(OC2=C(C1)O)=O FWYIBGHGBOVPNL-UHFFFAOYSA-N 0.000 description 1
- 230000036280 sedation Effects 0.000 description 1
- 239000000932 sedative agent Substances 0.000 description 1
- 230000001624 sedative effect Effects 0.000 description 1
- 230000036299 sexual function Effects 0.000 description 1
- SQVRNKJHWKZAKO-OQPLDHBCSA-N sialic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)OC1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-OQPLDHBCSA-N 0.000 description 1
- KZJWDPNRJALLNS-VJSFXXLFSA-N sitosterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@@H](CC)C(C)C)[C@@]1(C)CC2 KZJWDPNRJALLNS-VJSFXXLFSA-N 0.000 description 1
- 229950005143 sitosterol Drugs 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000010025 steaming Methods 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- VSJGJMKGNMDJCI-QXSNVGMTSA-N sweroside Natural products OC[C@H]1O[C@H](O[C@@H]2OC=C3[C@@H](CCOC3=O)[C@H]2C=C)[C@H](O)[C@@H](O)[C@@H]1O VSJGJMKGNMDJCI-QXSNVGMTSA-N 0.000 description 1
- 210000004233 talus Anatomy 0.000 description 1
- 239000001648 tannin Substances 0.000 description 1
- 235000018553 tannin Nutrition 0.000 description 1
- 229920001864 tannin Polymers 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 229940116411 terpineol Drugs 0.000 description 1
- 229960003604 testosterone Drugs 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 229960003495 thiamine Drugs 0.000 description 1
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 1
- 230000035922 thirst Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- KBPHJBAIARWVSC-XQIHNALSSA-N trans-lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C KBPHJBAIARWVSC-XQIHNALSSA-N 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 238000002137 ultrasound extraction Methods 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
- 230000008728 vascular permeability Effects 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- NCYCYZXNIZJOKI-UHFFFAOYSA-N vitamin A aldehyde Natural products O=CC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C NCYCYZXNIZJOKI-UHFFFAOYSA-N 0.000 description 1
- 235000019156 vitamin B Nutrition 0.000 description 1
- 239000011720 vitamin B Substances 0.000 description 1
- 235000010374 vitamin B1 Nutrition 0.000 description 1
- 239000011691 vitamin B1 Substances 0.000 description 1
- 235000019164 vitamin B2 Nutrition 0.000 description 1
- 239000011716 vitamin B2 Substances 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 230000002087 whitening effect Effects 0.000 description 1
- 235000010930 zeaxanthin Nutrition 0.000 description 1
- 239000001775 zeaxanthin Substances 0.000 description 1
- 229940043269 zeaxanthin Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/882—Acoraceae (Calamus family), e.g. sweetflag or Acorus calamus
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
- A23L29/065—Microorganisms
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
- A61K36/076—Poria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/232—Angelica
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/40—Cornaceae (Dogwood family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/538—Schizonepeta
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/69—Polygalaceae (Milkwort family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/80—Scrophulariaceae (Figwort family)
- A61K36/804—Rehmannia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/83—Thymelaeaceae (Mezereum family), e.g. leatherwood or false ohelo
- A61K36/835—Aquilaria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/898—Orchidaceae (Orchid family)
- A61K36/8988—Gastrodia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
- A61K36/9068—Zingiber, e.g. garden ginger
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/322—Foods, ingredients or supplements having a functional effect on health having an effect on the health of the nervous system or on mental function
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/10—Preparation or pretreatment of starting material
- A61K2236/19—Preparation or pretreatment of starting material involving fermentation using yeast, bacteria or both; enzymatic treatment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Mycology (AREA)
- Public Health (AREA)
- Botany (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Medical Informatics (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Neurosurgery (AREA)
- Nutrition Science (AREA)
- Biomedical Technology (AREA)
- Polymers & Plastics (AREA)
- Neurology (AREA)
- Gastroenterology & Hepatology (AREA)
- Food Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Description
본 발명은 조기치매 완화 및 예방용 발효안심침향단 및 그 제조방법에 관한 것으로, 더욱 상세하게는 치매에 유효한 약재를 전탕하여 얻은 추출농축액에, 한약재분말, 복합발효분말 및 신곡을 반죽하여 혼합 발효시킴으로써, 치매에 대한 우수한 효능을 가지면서 한약재 쓴맛과 특유의 향을 저감하고, 보관성 및 섭취성이 용이하도록 하는 조기치매 완화 및 예방용 발효안심침향단 및 그 제조방법에 관한 것이다.The present invention relates to a fermented relief acupuncture for the alleviation and prevention of early dementia, and a method for manufacturing the same, and more particularly, to an extract obtained by boiling a medicinal material effective for dementia, kneading herbal medicine powder, complex fermented powder and new grains to ferment By doing so, it relates to a fermented relief acupuncture for premature dementia alleviation and prevention and a method of manufacturing the same, which reduces bitter taste and peculiar aroma of herbal medicinal herbs while having excellent efficacy against dementia, and facilitates storage and intake.
치매란 성장기에는 정상적인 지적 수준을 유지하다가 후천적으로 인지기능의 손상 및 인격의 변화가 발생하여, 일상생활에 영향을 미치는 넓은 범위의 뇌 손상 질환이다. 65세 이상에서 대부분 발병하는 노인성 질환으로 보통 알려져 왔으나, 65세 이전에도 '초로기 치매'의 형태로 치매 증상이 나타나는 사례는 꾸준히 보고되고 있다. 또한, 고령화 사회로 진입함에 따라 치매는 중대한 의료, 사회 및 경제적 문제로 대두되고 있다.Dementia is a wide range of brain damage diseases that affects daily life by maintaining a normal intellectual level during the growth phase, but by acquiring cognitive impairment and changes in personality. It has been commonly known as a senile disease that most of the people over 65 years of age, but even before the age of 65, cases of dementia symptoms appearing in the form of'early dementia' have been reported steadily. In addition, as it enters an aging society, dementia is emerging as a serious medical, social and economic problem.
치매의 종류에는 알츠하이머 치매가 전체에서 가장 높은 빈도를 나타내며, 혈관성 치매, 레비소체병, 파킨슨병 및 크로이츠-야코프병 순서로 치매질환이 발병하고, 한 환자에게서 여러 치매 형태들이 복합적으로 나타날 수 있다. As for the type of dementia, Alzheimer's dementia has the highest frequency in the whole, and dementia develops in the order of vascular dementia, Lewy body disease, Parkinson's disease, and Creutz-Yakov's disease, and multiple forms of dementia can appear in a single patient.
알츠하이머형 치매에 효과를 보이는 보편적인 양약 치료제로는 도네피질이 있는데, 이는 뇌에서 기억, 인지기능에 중요한 역할을 하는 신경전달물질인 아세틸콜린을 정상적으로 유지하도록 기능을 수행한다고 알려져 있다.As a general herbal remedy for Alzheimer's-type dementia, there is donee cortex, which is known to function to maintain normal acetylcholine, a neurotransmitter that plays an important role in memory and cognitive functions in the brain.
그러나 도네피질의 양약 치료제는 고도 알츠하이머 환자들의 경우 복용량이 증가할수록 소화불량, 공격성 증가 등의 부작용이 보고되고 있다. However, in patients with advanced Alzheimer's disease, side effects such as indigestion and increased aggression have been reported as the dose increases for the Western Cortex treatment.
상기 양약 치료제의 부작용을 저감시키기 위한 일환으로, 생약성분으로 이루어진 한약재를 배합한 한약처방에 대한 관심이 높아지고 있으며, 근래에는 치매 관련 한약처방이 과학적인 임상실험을 거쳐 점차 규명되고 있다. As a part of reducing the side effects of the herbal remedy, interest in herbal prescriptions formulated with herbal ingredients consisting of herbal ingredients is increasing, and in recent years, herbal prescriptions related to dementia have been gradually identified through scientific clinical trials.
그 일례로, 선행기술문헌 1은 파킨슨병에 유용한 성분이 백복령, 백작약, 창출, 천궁, 조구등 등에 포함되어 있다고 보고하고 있으며, 상기 성분을 함유하는 다양한 제제 형태의 의약품을 개발하려는 노력이 진행되고 있다.As an example, prior art document 1 reports that ingredients useful for Parkinson's disease are included in Baekbokryeong, Baekjak, Jeon, Cheongung, Jogu, etc., and efforts are being made to develop pharmaceuticals in various formulations containing the above ingredients. .
한편, 일부 보고에서는 한약재성분을 포함한 전문의약품으로의 접근과 더불어 식품으로의 제형이 제안되고 있다. On the other hand, in some reports, a formulation as a food is proposed along with access to prescription drugs including herbal ingredients.
선행기술문헌 2는 인삼, 산수유, 모과, 오미자를 혼합하여 증류수를 가한 뒤 열탕추출기에서 가열하여 얻어진 한약재 추출액을 통해, 치매 예방에 도움을 주는 건강음료를 개시하고 있다. Prior Art Literature 2 discloses a health drink that helps prevent dementia through an herbal extract obtained by mixing ginseng, cornus, quince, and schisandra into distilled water and then heating it in a hot water extractor.
또한, 선행기술문헌 3은 사향 분말, 녹용 분말, 당귀 분말 및 천삼 분말을 포함하는 내층과, 상기 내층의 외면에 형성된 백복령 분말, 결명자 분말 및 황기 분말 등 1종 이상의 것을 포함하는 외층으로 구성된 기억력 및 학습능력 향상용 공진단을 개시하고 있다. In addition, prior art document 3 is a memory composed of an inner layer comprising musk powder, antler powder, angelica powder, and cheonsam powder, and an outer layer comprising at least one kind of Baekbokryong powder, Cassia tora powder and Astragalus powder formed on the outer surface of the inner layer. The public diagnosis team for improving learning ability is being launched.
상기 사향 성분은 사향노루의 사향선(腺)을 건조시켜 얻는 분비물인 사향의 가루에서 채취된 것으로, 위장과 정신을 맑게 해주고 강심제나 각성제로 주로 사용되는 약재이다.The musk ingredient is obtained from musk powder, a secretion obtained by drying the musk gland of musk deer, and is a medicinal material mainly used as a cardiac or stimulant to clear the stomach and mind.
그러나 상기 사향 성분은 가격이 고가로 책정되어 있고 수급이 어렵기 때문에, 사향이 포함된 공진단을 식품으로 등록하여 대량생산하기에는 한계가 있다.However, since the price of the musk ingredient is set at a high price and it is difficult to supply and demand, there is a limit to mass production by registering Gongjindan containing musk as a food product.
따라서, 사향 성분을 침향으로 대체하여 식품으로 적용한 연구가 진행되고 있는데, 선행기술문헌 4에는 침향을 포함하는 공진액 조성물과 그 제조방법을 개시함에 있어, 침향을 분쇄 후 에탄올 수용액에 침지추출하는 법제화 단계와, 법제된 약재를 추출 보자기에 적층하고, 용매를 혼합하여 약재 추출물을 제조한 다음, 상기 약재 추출물을 농축하여 당류와 혼합하는 단계를 포함한다. Therefore, research in which the musk component is replaced with aloes and applied as a food is in progress.In prior art document 4, in disclosing a conjugate composition containing aloes and a method for manufacturing the same, a law was made in which aloes were pulverized and immersed in an aqueous ethanol solution. And stacking the legally formulated medicinal material on an extraction cloth, mixing a solvent to prepare a medicinal material extract, and then concentrating the medicinal material extract and mixing it with sugars.
그러나 상기 약재 추출물을 제조하기 위하여, 장시간(최장 26시간) 추출을 진행하는 1,2 차 추출단계와, 상기 1,2 차 추출단계 사이에 초음파 추출 단계를 포함한다. 또한, 별도의 용매추출단계, 멸균단계도 포함하고 있어 공정 상 여러 단계를 거쳐야 하는 번거로움이 있다. However, in order to prepare the herbal extract, it includes a first and second extraction step in which extraction is performed for a long time (up to 26 hours), and an ultrasonic extraction step between the first and second extraction steps. In addition, since a separate solvent extraction step and a sterilization step are included, there is an inconvenience of having to go through several steps in the process.
이에 본 발명자들은 종래 문제점을 개선하고자 노력한 결과, 한약재성분을 탐색하는 과정에 고가의 사향이 각성, 흥분 작용이 있다면, 상대적으로 저렴하면서도 진정, 안정 작용을 발현하는 침향을 대체 사용하도록 하여, 침향, 초석잠 및 포공영을 함유하는 한약재분말, 복합발효분말 및 신곡을 치매에 유효한 약재로부터 추출된 추출농축액과 반죽하여 혼합 발효 후 제환된 발효안심침향단을 제공하고, 상기 발효안심침향단의 조기치매 완화 및 예방에 대한 우수한 효능을 확인함으로써, 본 발명을 완성하였다. Accordingly, as a result of the present inventors trying to improve the conventional problems, if expensive musk has arousal and excitatory action in the process of searching for herbal ingredients, a relatively inexpensive yet soothing, stabilizing action can be used instead of acupuncture, acupuncture, Herbal medicine powder, complex fermented powder, and new grains containing Choseokjam and Pogongyeong are kneaded with extracts extracted from medicinal materials effective against dementia to provide fermented relief acupuncture after mixing and fermentation, and early dementia relief of the fermented relief acupuncture. And by confirming the excellent efficacy for prevention, the present invention was completed.
본 발명의 목적은 조기치매 완화 및 예방용 발효안심침향단을 제공하는 것이다. An object of the present invention is to provide a fermented relief acupuncture group for alleviation and prevention of early dementia.
본 발명의 다른 목적은 조기치매 완화 및 예방용 발효안심침향단의 제조방법을 제공하는 것이다. Another object of the present invention is to provide a method for preparing fermented relief acupuncture for early dementia alleviation and prevention.
상기 목적을 달성하기 위하여, 본 발명은 석창포, 백복신, 원지 및 형개수로 이루어진 군에서 선택된 적어도 어느 하나 이상의 약재를 이용하여 얻은 추출농축액에, 침향, 초석잠 및 포공영을 함유하는 한약재분말, 복합발효분말 및 신곡이 혼합되어 발효 후 제환된, 조기치매 완화 및 예방용 발효안심침향단을 제공한다.In order to achieve the above object, the present invention is a herbal medicine powder, complex fermented powder containing acupuncture, choseokjam and pogongyeong in the extract obtained by using at least one or more medicinal materials selected from the group consisting of Seokchangpo, Baekbokshin, Wonji and Hyunggae. And it provides a fermented safe acupuncture group for relieving and preventing early dementia, which is mixed with new grains and reconstituted after fermentation.
구체적으로, 상기 추출농축액이 석창포 20 내지 40중량%, 백복신 20 내지 40중량%, 원지 20 내지 40중량% 및 형개수 5 내지 10중량%로부터 추출된 것이다. Specifically, the extract concentrate is extracted from seokchangpo 20 to 40% by weight, baekbokshin 20 to 40% by weight, base paper 20 to 40% by weight, and mold number 5 to 10% by weight.
또한, 한약재분말은 침향, 초석잠 및 포공영에, 청국장발효분말, 녹용발효농축분말, 산수유, 당귀, 진피, 길경, 오미자, 숙지황, 홍삼, 갈근, 복령, 구기자, 창출, 홍국, 생강, 천마로 이루어진 군에서 선택된 어느 하나 이상이 더 포함될 수 있다. In addition, herbal medicinal powders include acupuncture, choseokjam and pogongyeong, cheonggukjang fermented powder, deer antler fermented concentrated powder, cornus milk, angelica, dermis, gilkyung, schisandra, sukjihwang, red ginseng, galgeun, bokryeong, gugija, creation, red guk, ginger, cheonmaro. Any one or more selected from the group consisting of may be further included.
본 발명의 조기치매 완화 및 예방용 발효안심침향단에 있어서, 복합발효분말은 효모 및 고초균으로 이루어진 군에서 선택된 어느 하나 이상인 것이다. 이때, 상기 효모가 사카로마이세스속(Saccharomyces,sp.), 시조사카로마이세스속(Shizosaccharomyces,sp.) 및 클루레로 마이세스 속(Klureromyces sp.)으로 이루어진 군에서 선택된 어느 하나 이상인 것이다. In the fermented safe acupuncture group for alleviation and prevention of early dementia of the present invention, the compound fermented powder is one or more selected from the group consisting of yeast and Bacillus bacillus. At this time, the yeast is one or more selected from the group consisting of Saccharomyces, sp., Shizosaccharomyces, sp., and Klureromyces sp. .
또한, 본 발명은 석창포, 백복신, 원지 및 형개수로 이루어진 군에서 선택된 적어도 어느 하나 이상의 약재를 이용하여 추출농축액을 획득하는 제1단계; 상기 추출농축액에, 침향, 초석잠 및 포공영을 함유하는 한약재분말, 복합발효분말 및 신곡을 반죽하여 혼합 발효하는 제2단계; 상기 발효된 반죽을 건조시키고 분쇄하여 발효약재분말을 획득하는 제3단계; 및 상기 발효약재분말과 꿀을 배합하여 제환하는 제4단계를 포함하는 발효안심침향단의 제조방법을 제공한다. In addition, the present invention is a first step of obtaining an extract concentrate using at least one or more medicinal materials selected from the group consisting of Seokchangpo, Baekbokshin, Wonji and Hyunggae; A second step of kneading and fermenting the herbal medicine powder, complex fermented powder and new grains containing acupuncture, choseokjam and pogongyeong in the extract concentrate; A third step of drying and pulverizing the fermented dough to obtain a fermented medicinal powder; And it provides a method for manufacturing a fermented relief acupuncture step comprising a fourth step of blending the fermented medicinal powder and honey.
본 발명의 제조방법에 있어서, 추출농축액은 석창포 20 내지 40중량%, 백복신 20 내지 40중량%, 원지 20 내지 40중량% 및 형개수 5 내지 10중량%로부터 추출된다. In the production method of the present invention, the extract concentrate is extracted from 20 to 40% by weight of seokchangpo, 20 to 40% by weight of baekbokshin, 20 to 40% by weight of the base paper, and 5 to 10% by weight of the number of molds.
또한, 상기 추출농축액에 한약재분말을 포함할 수 있으며, 상기 한약재분말이 청국장발효분말, 녹용발효농축분말, 산수유, 당귀, 진피, 길경, 오미자, 숙지황, 홍삼, 갈근, 복령, 구기자, 창출, 홍국, 생강, 천마로 이루어진 군에서 선택된 어느 하나 이상이 더 혼합된다. In addition, the extract may contain herbal medicine powder, and the herbal medicine powder is cheonggukjang fermented powder, antler fermented concentrated powder, cornus milk, angelica, dermis, gilgyeong, schisandra chinensis, sukjihwang, red ginseng, galgeun, bokryeong, gugija, jinja, red ginseng , Ginger, any one or more selected from the group consisting of cheonma is further mixed.
상기 복합발효분말이 효모 및 고초균으로 이루어진 군에서 선택된 어느 하나 이상인 것이다. 상기 효모가 사카로마이세스속(Saccharomyces, sp.), 시조사카로마이세스속(Shizosaccharomyces, sp.) 및 클루레로 마이세스 속(Klureromyces sp.)으로 이루어진 군에서 선택된 어느 하나 이상인 것이다. The complex fermented powder is any one or more selected from the group consisting of yeast and Bacillus bacillus. The yeast is any one or more selected from the group consisting of Saccharomyces, sp., Shizosaccharomyces, sp., and Klureromyces sp.
또한, 상기 추출농축액 100 중량부에 대하여, 복합발효분말은 1 내지 3 중량부 혼합되는 것이고, 신곡은 10 내지 30 중량부로 혼합된다. In addition, with respect to 100 parts by weight of the extract concentrate, 1 to 3 parts by weight of the complex fermented powder is mixed, and 10 to 30 parts by weight of new grains are mixed.
본 발명의 제조방법에 따르면, 상기 혼합 발효는 30 내지 50℃에서 48 내지 96시간동안 수행된 것이다.According to the manufacturing method of the present invention, the mixed fermentation is performed at 30 to 50° C. for 48 to 96 hours.
상기 발효된 반죽을 건조시키고 분쇄된 발효약재분말이 180 내지 220입도로 분쇄된 것이다. The fermented dough is dried and the pulverized fermented medicinal powder is pulverized into 180 to 220 particles.
이후, 상기 발효약재분말 60 내지 90중량% 및 꿀 10 내지 40중량%을 배합하여 제환한다.Thereafter, 60 to 90% by weight of the fermented medicinal powder and 10 to 40% by weight of honey are blended to form a pill.
본 발명에 따라, 치매에 유효한 약재를 전탕하여 얻은 추출농축액에, 한약재분말, 복합발효분말 및 신곡을 반죽하여 혼합 발효시킴으로써, 조기 치매 완화 및 예방 효능을 가지는 발효안심침향단을 제공할 수 있다.According to the present invention, a fermented relief acupuncture dan having an early dementia alleviation and prevention effect can be provided by kneading and fermenting herbal medicine powder, complex fermented powder, and new grains in the extract obtained by distilling a medicinal material effective for dementia.
특히, 상기 치매에 유효한 약재로 사용된 침향은 종래 고가의 사향을 대체할 수 있어 경제적이고, 사향이 각성, 흥분 작용이 있는 반면, 침향은 진정·안정 작용을 발현하므로, 본 발명의 조기 치매 완화 및 예방 효능을 가지는 발효안심침향단에 유용하다. In particular, acupuncture used as an effective medicine for dementia is economical as it can replace conventionally expensive musk, while musk has arousal and excitatory action, whereas acupuncture exhibits soothing and stabilizing effects, so that early dementia relief of the present invention And it is useful for fermented relief acupuncture dan having a preventive effect.
또한, 본 발명은 생약 성분인 한약재를 혼합 발효시킴으로써, 유효성분을 향상시키고 한약재 쓴맛과 특유의 향을 저감하며, 위, 간, 장의 부담을 덜도록 하였으며, 적정량의 꿀을 첨가하여 제환함으로써 보관성 및 섭취성이 우수한 발효안심침향단을 제공할 수 있다.In addition, the present invention is a mixture of herbal ingredients, which are herbal ingredients By fermentation, it improves the active ingredient, reduces the bitter taste and peculiar aroma of herbal medicines, relieves the burden on the stomach, liver, and intestines, and provides fermented relief acupuncture with excellent storage and intake by adding appropriate amount of honey can do.
이하, 본 발명을 상세히 설명한다. Hereinafter, the present invention will be described in detail.
본 발명은 석창포, 백복신, 원지 및 형개수로 이루어진 군에서 선택된 적어도 어느 하나 이상의 약재를 이용하여 얻은 추출농축액에, 침향, 초석잠 및 포공영을 함유하는 한약재분말, 복합발효분말 및 신곡이 혼합되어 발효 후 제환된, 조기치매 완화 및 예방용 발효안심침향단을 제공한다.The present invention is after fermentation by mixing the herbal medicine powder containing acupuncture, choseokjam and pogongyeong, complex fermented powder and new grains in the extract obtained using at least one or more medicinal materials selected from the group consisting of Seokchangpo, Baekbokshin, Wonji and Hyeonggaesu. Provides fermented safe acupuncture groups for alleviation and prevention of early dementia.
구체적으로, 본 발명의 추출농축액 획득에 이용되는 약재로는 석창포, 백복신, 원지 및 형개수로 이루어진 군에서 선택된 적어도 어느 하나 이상이 포함될 수 있다.Specifically, the medicinal material used to obtain the extract of the present invention may include at least one or more selected from the group consisting of Seokchangpo, Baekbokshin, Wonji, and Hyeonggaesu.
석창포는 천남성과에 속한 다년생 식물인 석창포(Acorus gramineus)의 근경을 건조한 것이다. 산속 계곡의 바위 틈에서 자생한다 하여 붙여진 이름이다. 성질이 따뜻하고 매운 맛이 난다. 잎과 꽃에 특유의 향이 있으며, 주로 뿌리를 약용한다. Seokchangpo is the dried rhizome of Acorus gramineus , a perennial plant belonging to the Chunnamdae family. It is named because it grows naturally in the cracks of rocks in mountain valleys. It has a warm and spicy taste. Leaves and flowers have a unique scent, and the roots are mainly used for medicinal purposes.
석창포는 귀와 눈을 밝게 하고 건망증을 치료하며, 정신을 깨우치고 뇌를 건강하게 한다고 알려져 있다. 전통적으로 신경정신과 질환 치료에 쓰이던 총명탕의 주요구성 약재였다.Seokchangpo is known to brighten ears and eyes, cure forgetfulness, awaken the mind, and make the brain healthy. It was a major component of Chongmyeong-tang, traditionally used to treat neuropsychiatric diseases.
특히, 기억력, 인지능력을 개선하여 치매 등의 질환을 치료하는 데 이용되어왔다. 석창포의 주성분 중 유게놀과 베타-아사론(Asarone)은 뇌세포의 칼슘 유입을 차단하여 뇌 신경을 보호하고 치매에 도움이 된다. In particular, it has been used to treat diseases such as dementia by improving memory and cognitive ability. Among the main components of Seokchangpo, eugenol and beta-asarone block the influx of calcium from brain cells to protect brain nerves and help against dementia.
약학회지 제51권 제6호 463~468p(2007년)에 소개된 논문에 의하면, 석창포의 유효성분인 (E), (Z)-아사론(Asarone), 세크손(Sekshon), 카리오필렌(Caryophyllene), 휴뮬렌(Humulene) 및 메틸루게놀(Methyleugenol) 6가지는 모두 기억력 증진에 관여한다고 보고되고 있다. According to the thesis introduced in the Journal of the Korean Journal of Pharmaceutical Sciences Vol. 51, No. 6 463~468p (2007), the active ingredients of Seokchangpo are (E), (Z)-Asarone, Sekshon, and caryophyllene. Caryophyllene), humulene, and methyleugenol are all reported to be involved in memory enhancement.
원지(遠志)는 말그대로 뜻을 오래 간직하는 약초라는 의미로, 원지과에 속하는 다년생 초본인 세엽원지(Polygala tenuifolia Willd.)의 뿌리를 건조하여 중심의 목부를 제거한 것을 약용으로 사용한다. 원지 또한 총명탕의 주재료이며, 학습과 기억력 개선 용도로 사용되어 왔다.Wonji (遠志) literally means a medicinal herb that retains its meaning for a long time. It is used for medicinal purposes by drying the root of Polygala tenuifolia Willd., a perennial herb belonging to the Wonji family. Wonji is also the main ingredient of Chongmyeongtang, and has been used to improve learning and memory.
원지의 함유성분으로는 폴리사카라이드, 사포닌, 크산톤 오르쏘-글리코사이드(xanthone o-glycosides) 등의 글리코사이드, 폴리갈리톨(polygalitol) 및 테뉴이겐넨(tenuigenen) 등이 있다. 이 성분들은 치매, 파킨슨 증상완화, 신경세포 보호 및 기억력 향상 효과가 있다. 또한, 신경안정, 거담, 불면을 치료하며, 강장제, 강정제로도 사용된다.Constituents of the base paper include polysaccharides, saponins, glycosides such as xanthone o-glycosides, polygalitol, and tenuigenen. These ingredients alleviate dementia, Parkinson's symptoms, protect nerve cells, and improve memory. In addition, it treats nervous stability, expectorance, and insomnia, and is also used as a tonic and gangrene.
백복신은 소나무 뿌리에 기생하는 잔나비걸상과의 복령(Poria cocos Wolf)의 균핵 사이로 뿌리가 관통한 것을 말한다. 복신은 주로 정신을 안정시키고 머리를 맑게 하는데 사용된다. 또한, 신경과민으로 인한 가슴 두근거림, 건망증, 유정 및 배와 전신이 붓는 증상 해결에 쓰인다. 약리작용으로는 이뇨, 항균작용, 장관이완작용, 궤양예방효과, 혈당강하작용, 심장수축력 증가, 면역증강작용, 항종양작용 등이 보고되고 있다.Baekbokshin refers to the penetration of the roots through the sclerotia of Poria cocos Wolf , a parasitic plant on the root of a pine tree. Fortune is mainly used to calm the mind and clear the head. It is also used to resolve the symptoms of heart palpitations caused by nervousness, forgetfulness, oil wells, and swelling of the stomach and whole body. As pharmacological action, diuresis, antibacterial action, intestinal relaxation action, ulcer prevention effect, blood sugar lowering action, heart contraction increase, immunity enhancing action, anti-tumor action, etc. have been reported.
형개수는 꿀풀과 식물인 형개(Schizonepeta tenuifolia var. japonica Kitagawa)의 꽃대로, 꽃 모양이 이삭 모양을 하고 있어 붙여진 이름이다. 아린 맛이 나고, 약간 따뜻한 성질을 띤다. 정유 성분 중에 d-Menthene, 리모넨(Limonene) 등이 함유되어 있는데, 이 성분들이 우수한 기관지확장 작용을 일으켜 천식을 가라앉히므로 임상에서 만성기관지염 치료로 쓰인다. 그 밖에도 진정작용 및 체온 강하작용을 한다. Hyeonggaesu is a flower of the lamiaceae plant Hyeonggae (Schizonepeta tenuifolia var. japonica Kitagawa ), and it is named because the flower has a spike shape. It has a bitter taste and is slightly warm. Among the essential oil ingredients, d-Menthene and limonene are contained, and these ingredients cause excellent bronchodilating action to alleviate asthma, so it is used clinically as a treatment for chronic bronchitis. In addition, it sedates and lowers body temperature.
약리 실험에서 형개수 탕약이 약한 해열 작용, 땀분비 촉진작용, 말초혈관 혈액순환을 빠르게 하는 작용, 진경작용, 소화작용 및 지혈작용을 한다고 보고되고 있다. 또한, 황색포도상구균, 디프테리아균에 대해 강한 항균 작용을 보이며, 탄저균, 연쇄상구균, 인플루엔자균, 이질균, 녹농균 및 결핵균에 대하여도 일정 억제 작용을 보인다. In pharmacological experiments, it has been reported that Hyeonggaesu-tang has a mild antipyretic effect, a sweat secretion promoting effect, a rapid effect of peripheral blood circulation, a spasmodic effect, a digestive effect, and a hemostasis effect. In addition, it shows a strong antibacterial action against Staphylococcus aureus and diphtheria, and also shows certain inhibitory action against anthrax, streptococci, influenza, dysentery, Pseudomonas aeruginosa and Mycobacterium tuberculosis.
본 발명의 실시예에 따른 추출농축액은 석창포 20 내지 40중량%, 백복신 20 내지 40중량%, 원지 20 내지 40중량% 및 형개수 5 내지 10중량%로부터 추출된 것이 바람직하다. The extract concentrate according to an embodiment of the present invention is preferably extracted from seokchangpo 20 to 40% by weight, baekbokshin 20 to 40% by weight, base paper 20 to 40% by weight, and mold number 5 to 10% by weight.
치매에 각기 다른 유효한 성분을 가지는 석창포, 백복신, 원지 및 형개수를 배합함으로써, 다양한 원인과 병변을 띠는 치매 군에 대한 포괄적인 치료 효과를 제시할 수 있다. 또한, 상기 석창포, 백복신, 원지 및 형개수의 조합을 통하여 조기치매 완화 및 예방에 관한 효능을 높일 수 있다. 그러나, 본 발명의 실시예에 따라 이용되는 약재의 조성 및 함량은 예시적인 것이며, 이에 한정하지 아니한다. By combining Seokchangpo, Baekbokshin, Wonji, and Hyeonggaesu, each having different effective ingredients for dementia, it is possible to present a comprehensive therapeutic effect for the dementia group with various causes and lesions. In addition, it is possible to increase the efficacy in relieving and preventing early dementia through the combination of the Seokchangpo, Baekbokshin, Wonji, and Hyeonggaesu. However, the composition and content of the medicinal material used according to the embodiment of the present invention are exemplary and are not limited thereto.
본 발명에 따른 한약재분말은 침향, 초석잠 및 포공영을 함유하는 것을 특징으로 한다. The herbal medicine powder according to the present invention is characterized by containing acupuncture, choseokjam and pogongyeong.
여기서, 침향은 침향나무(Aquilaria Crassna)의 수지가 침착된 수간목으로서, 물에 가라앉는 향나무란 뜻을 가진다. 물에 가라앉는 정도에 따라 품질이 결정되며, 침향의 핵심이 되는 성분 수지의 함량이 적을 수록 물에 가라앉지 않고 뜨게 된다.Here, aloes refers to a juniper that sinks in water as the bestial tree in which the resin of Aquilaria Crassna is deposited. The quality is determined by the degree of sinking in water, and the smaller the content of the component resin that is the core of acupuncture, the more it floats without sinking.
<동의보감>에 따르면 침향은 나쁜 기운을 없애고, 정신을 편안하게 하는 안정작용, 기운의 원활한 순환 작용이 있다고 기록되어 있다. According to <Donguibogam>, it is recorded that acupuncture removes bad energy, calms the mind, and has a smooth circulation of energy.
구체적으로, 침향에는 중추신경 이완과 머리를 맑게 하는 작용을 하는 아가로스피롤(Agarospirol), 중추신경계 안정작용을 하는 아가로퓨란(Agarofuran)과 디하이드로퓨키논(Dehydrofukinone) 및 항경련 작용을 하는 테르피네올(Terpineol)이 함유되어 있으며, 이를 통해 신경 진정·안정 작용이 가능하고, 기억력· 인지력 등을 향상시킬 수 있다.Specifically, acupuncture includes agarosepyrol (Agarospirol) that relaxes the central nervous system and clears the head, agarofuran (Agarofuran) that stabilizes the central nervous system, and dehydrofukinone (Dehydrofukinone), which has an anticonvulsant effect. Terpineol is contained, through which it can calm and stabilize nerves, and improve memory and cognition.
또한, 침향은 몸의 기운이 머리 끝부터 발 끝까지 구석구석 미치게 하기 때문에 다른 약재와 혼용하면 약효가 필요한 곳까지 잘 전달되게 한다. In addition, acupuncture makes the body's energy go from head to toe to every corner, so if it is mixed with other medicinal materials, it is well delivered to the place where the medicinal effect is needed.
최근에는 침향의 진정작용, 항종양 및 항암작용이 밝혀졌으며, 동물실험에서 알츠하이머, 파킨슨 질환에 효과가 있었는데, 이는 중풍이나 뇌졸중 같은 뇌혈관 질환에 응용할 수 있는 근거를 제시한 바 있다[국제공개특허 제2019-151547호 참조].Recently, acupuncture has been found to have sedative, anti-tumor, and anti-cancer effects, and has been effective in Alzheimer's and Parkinson's disease in animal experiments, which has provided evidence that it can be applied to cerebrovascular diseases such as stroke and stroke. No. 2019-151547].
특히, 치매에 유효한 약재로 사용된 침향은 종래 고가의 사향을 대체할 수 있어 경제적이고, 사향이 각성, 흥분 작용이 있는 반면, 침향은 진정·안정 작용을 발현하므로, 본 발명의 조기 치매 완화 및 예방 효능을 가지는 발효안심침향단에 유용하다. In particular, acupuncture used as an effective medicine for dementia is economical as it can replace conventionally expensive musk, while musk has an arousal and excitatory action, whereas acupuncture has a soothing and stabilizing action, so the early dementia alleviation of the present invention and It is useful for fermented relief acupuncture with preventive effect.
초석잠(Stachys sieboldii MIQ.)은 꿀풀과 석잠풀속의 여러해살이에 속하는 석잠풀의 뿌리이다. 뿌리가 누에모양을 하고 있어서 식물의 동충하초라고 불리운다.Choseokjam ( Stachys sieboldii MIQ. ) is the root of Seokjampul, belonging to the perennial of the genus Lamiaceae. Because the roots are silkworm-shaped, they are called cordyceps of plants.
한국, 시베리아 동부, 중국 동북부, 일본, 캄차카반도 등지의 산과 들의 습지에 널리 분포한다. It is widely distributed in mountains and fields of Korea, eastern Siberia, northeastern China, Japan, and Kamchatka Peninsula.
초석잠에는 항산화, 항노화, 항암 성분 등이 풍부하다. 특히 한방에서는 뇌력증진, 노인성 치매 방지 및 뇌 경색 예방에 대한 효능이 인정되어 이와 관련된 용도로 많이 쓰이고 있다. 구체적으로, 뇌세포 활성화, 기억력 증진, 혈액순환 촉진 작용이 있어 치매예방, 기혈순환, 중풍, 신경통, 고혈압, 당뇨병, 동맥경화, 간경화 및 지방간 예방 등의 약효가 있다고 알려져 있다.Choseokjam is rich in antioxidant, anti-aging, and anti-cancer properties. In particular, oriental medicine has been recognized for its efficacy in enhancing brain strength, preventing senile dementia, and preventing cerebral infarction, so it is widely used for related purposes. Specifically, it is known to have medicinal effects such as dementia prevention, air circulation, stroke, neuralgia, hypertension, diabetes, arteriosclerosis, liver cirrhosis, and fatty liver prevention because it has the effect of activating brain cells, enhancing memory, and promoting blood circulation.
포공영은 민들레(Taraxacum platycarpum H. Dahlstedt)의 지상부위 전초를 말한다. 주로 피부과 및 염증질환에 많이 사용되어 왔다. 포공영 추출물은 염증유발물질을 억제하여 아토피피부염을 완화시키고, 헬리코박터 파일로리(Helicobacter pylori)균에 대한 항균작용을 하고 활성산소를 제거하여 위장점막 보호작용을 한다. Pogongyeong refers to the above-ground outpost of the dandelion ( Taraxacum platycarpum H. Dahlstedt ). It has been mainly used in dermatology and inflammatory diseases. Pogongyoung extract relieves atopic dermatitis by inhibiting inflammatory substances, acts as an antibacterial against Helicobacter pylori, and protects the gastrointestinal mucosa by removing active oxygen.
최근에는 포공영 추출물이 건망증, 치매, 알츠하이머 질환, 파킨슨 질환, 뇌졸중, 중풍 또는 헌팅턴 질환과 같은 기억인지력 장애를 수반하는 퇴행성 뇌질환의 치료, 개선 및 예방 효과가 있음을 제시하는 특허문헌(대한민국등록특허 제1380568호(2014.04.02. 공고))이 공지된 바 있다. In recent years, a patent document showing that Pogongyoung extract has the effect of treating, improving, and preventing degenerative brain diseases accompanying memory cognitive impairment such as forgetfulness, dementia, Alzheimer's disease, Parkinson's disease, stroke, stroke, or Huntington's disease. No. 1380568 (announced on April 02, 2014) has been known.
본 발명의 침향, 초석잠 및 포공영을 함유하는 한약재분말은 청국장발효분말, 녹용발효농축분말, 산수유, 당귀, 진피, 길경, 오미자, 숙지황, 홍삼, 갈근, 복령, 구기자, 창출, 홍국, 생강, 천마로 이루어진 군에서 선택된 어느 하나 이상이 더 포함될 수 있다. 상기 한약재분말의 구성이 모두 포함되는 것이 탁월한 효능 구현을 위해 이상적일 수 있으나, 이에 한정하지 아니한다. Herbal medicine powder containing acupuncture, choseokjam and pogongyeong of the present invention is cheonggukjang fermented powder, deer antler fermented concentrated powder, cornus milk, angelica, dermis, gilkyung, schisandra chinensis, sukjihwang, red ginseng, galgeun, bokryeong, gojija, jingeung, red ginseng, ginger, Any one or more selected from the group consisting of cheonma may be further included. It may be ideal for realizing excellent efficacy that all the composition of the herbal medicine powder is included, but is not limited thereto.
청국장발효분말은 대두를 전통적인 방식으로 발효시켜서 만든 청국장을 발효시켜 분말화 한 것이다. 영양분이 풍부하고, 항암, 염증개선, 면역력 증진, 변비개선, 다이어트 및 노화방지에 도움을 준다. Cheonggukjang fermented powder is powdered by fermenting cheonggukjang made by fermenting soybeans in a traditional way. Rich in nutrients, it helps anti-cancer, inflammation, immunity, constipation, diet and anti-aging.
특히, 청국장발효분말은 치매환자에게 부족한 아세틸콜린이라는 신경전달물질의 양을 증가시켜, 노인성 치매 예방에 도움이 된다.In particular, Cheonggukjang fermented powder increases the amount of a neurotransmitter called acetylcholine, which is insufficient in dementia patients, and is helpful in preventing senile dementia.
나토키나제 성분은 혈전 감소, 고혈압 완화, 혈당 조절의 효과가 있다. 또한, 발효균에 의해 생성되는 강력한 단백질 분해 효소는 소화를 용이하게 하며, 발효과정 중에 비타민 B2, 칼슘 등의 함량이 증가하며, 폴리글루탐산을 주성분으로 하는 끈끈한 점액성 물질이 생성되는데, 이 물질은 칼슘 흡수를 돕는다. 생리활성물질인 이소플라본이 발효를 거치면 흡수가 용이한 구조로 바뀌어 미발효된 콩 대비 이용성이 향상되며, 이는 골다공증 진행억제 및 예방에 도움을 준다. Nattokinase is effective in reducing blood clots, relieving hypertension, and regulating blood sugar. In addition, strong proteolytic enzymes produced by fermenting bacteria facilitate digestion, and the content of vitamin B2 and calcium increases during the fermentation process, and a sticky, mucous substance mainly composed of polyglutamic acid is produced, which is calcium. Aids in absorption. When isoflavone, a physiologically active substance, is fermented, it changes into a structure that is easily absorbed, improving availability compared to unfermented soybeans, which helps to inhibit and prevent the progression of osteoporosis.
녹용은 매화록, 마록의 수사슴의 뿔이 딱딱하게 각질화되기 전에 절단한 것이다. 녹용에는 콜라겐, 회분, 칼슘을 비롯한 무기질 성분과 단백질, 지방, 글리코사미노글리칸(glycosaminoglycans), 시알산(sialic acid), 우론산(uronicacid), 인슐린 유사 성장인자, 유즙분비 호르몬, 황체형성호르몬, 난포자극 호르몬 및 테스토스테론 등 다양한 성분이 함유되어 있다. The antlers are cut before the horns of the stag of plum and marok are hardly keratinized. Deer antler contains minerals including collagen, ash, calcium, protein, fat, glycosaminoglycans, sialic acid, uronic acid, insulin-like growth factor, milk secretion hormone, luteinizing hormone. , Follicle-stimulating hormone and testosterone.
또한, 녹용은 오래 전부터 한방에서 우수한 보혈강장제로서, 허약한 체질 치료와 예방에 다빈도로 사용되어왔다. 녹용의 약리적 효능에는 신경쇠약, 강장작용, 빈혈, 관절염, 성기능개선, 항노화, 면역강화, 조혈작용, 항혈전, 혈압강하, 항피로, 항스트레스, 항염증, 콜레스테롤 저하 및 면역활성 증가 등이 있다.In addition, deer antler has long been used as an excellent tonic in oriental medicine, and has been frequently used in the treatment and prevention of weak constitutions. The pharmacological effects of deer antler include nervous breakdown, tonic effect, anemia, arthritis, sexual function improvement, anti-aging, immunity strengthening, hematopoietic effect, antithrombosis, lowering blood pressure, anti-fatigue, anti-stress, anti-inflammatory, cholesterol lowering, and increasing immune activity. have.
산수유는 층층나무과에 속한 낙엽소교목인 산수유나무의 열매로, 다양한 유기산과, 로가닌(loganin), 스웨로시드(sweroside)와 같은 이리도이드(iridoid) 배당체, 탄닌(tannin)류 및 비타민이 함유되어 있다. 산수유는 단백질 소화, 이뇨, 간보호 작용을 한다. 특히 로가닌(loganin) 성분은 산화적 스트레스를 완화시켜주고, 인지력 향상 기능을 가지고 있다고 밝혀져 있다. 당뇨개선효과와 면역력증강 효과도 있다.Cornus is the fruit of a deciduous tree, a deciduous tree belonging to the dogwood family, and contains various organic acids, iridoid glycosides such as loganin and sweroside, tannins, and vitamins. Has been. Cornus milk digests protein, diuresis, and protects the liver. In particular, it has been found that loganin relieves oxidative stress and has cognitive enhancement functions. It has the effect of improving diabetes and enhancing immunity.
당귀는 미나리과 당귀속에 손하는 참당귀의 뿌리를 의미한다. 당귀의 성분에는 유기산, 프랄리드(Phthalides), 다당류 등이 있다. 기억개선, 조혈작용, 면역조절활성, 항산화작용, 간보호, 위장보호 활성 및 항당뇨 활성을 가진다.Angelica refers to the root of Angelica Angelica, which is in the parsley family. Ingredients of Angelicae include organic acids, Phhalides, and polysaccharides. It has memory improvement, hematopoietic activity, immunomodulatory activity, antioxidant activity, liver protection, gastrointestinal protection activity, and antidiabetic activity.
진피는 귤나무의 성숙한 과실의 열매껍질로서, 비타민류, 리모노이드(limonoid)류 및 플라보노이드(Flavonoid)류 등의 화합물을 함유하고 있고, 특히 플라보노이드(Flavonoid)류의 주요성분으로 헤스페리딘(hesperidin), 나린진(naringin) 등이 있다. 진피는 건위약으로 위장 평활근 이완, 위액분비 촉진, 항알레르기 효과, 항위궤양 작용, 이담, 혈관투과성 억제 및 항산화 작용이 있다.The dermis is the fruit bark of the mature fruit of the tangerine tree, and contains compounds such as vitamins, limonoids and flavonoids.In particular, hesperidin, as a major component of flavonoids, Naringin and others. The dermis is a tendon placebo and has gastrointestinal smooth muscle relaxation, gastric juice secretion, anti-allergic effect, anti-gastric ulcer action, ear sputum, vascular permeability inhibition, and antioxidant activity.
길경은 도라지의 뿌리로, 다량의 사포닌이 함유되어 있다. 이중 플라티코돈 디(platycodin D)라는 성분은 항암활성 효과, 항염증 효과, 항비만 효과 및 콜레스테롤 저하 효과 등이 있다. 한방에서는 질경을 호흡기 질환에 대한 대표적인 거담 진해제로 사용한다.Gilkyung is the root of bellflower and contains a large amount of saponin. Among them, a component called Platycodin D has anti-cancer activity, anti-inflammatory effect, anti-obesity effect, and cholesterol-lowering effect. In oriental medicine, plantain is used as a representative expectorant antitussive for respiratory diseases.
오미자는 주로 열매를 약용으로 사용하는데, 수분, 단백질 및 지방질 등으로 구성되는 열매의 대표성분은 쉬잔드린(schizandrin)이다. 약리적으로 치매예방 효과, 간기능 개선 효과, 항 비만 효과, 진해거담 효과 및 항스트레스 효과 등이 있다. 특히나, 오미자의 고미신 A(Gomisin A) 및 쉬잔드린(schizandrin) 성분은 알츠하이머병의 예방 및 치료에 도움이 되는 것으로 공지되어 있다. Schisandra chinensis is mainly used for medicinal purposes, and the representative component of the fruit composed of moisture, protein, and fat is schizandrin. Pharmacologically, it has dementia prevention effect, liver function improvement effect, anti-obesity effect, antitussive expectorant effect, and anti-stress effect. In particular, Gomisin A and schizandrin components of Schisandra chinensis are known to be helpful in the prevention and treatment of Alzheimer's disease.
숙지황은 지황의 뿌리를 구증구포(九蒸九曝; 아홉번 찌고 말림)한 것으로, 카타폴(catapol), 레마닌(rehmanin), 카로틴(carotene), 베타-시토스테롤(β-sitosterol), 5-히드록시메틸푸르푸랄(5-Hydroxymethylfurfural), 비타민 A와, 글루코오스, 라피노오스(raffinose) 및 만노트리오스(mannotriose)를 비롯한 당류를 주요성분으로 한다.Sukjihwang is the root of Rehmannia (九蒸九曝; steamed and dried nine times), catapol, lemanin, carotene, beta-sitosterol, 5- It contains hydroxymethylfurfural (5-Hydroxymethylfurfural), vitamin A, and sugars including glucose, raffinose and mannotriose as main components.
주로 보혈 강장제, 지혈제 및 해열제로 사용되며, 빈혈, 폐결핵, 허약증, 남성불임 등에도 쓰인다. 주름 개선효과와 미백효과, 혈압강하 효과도 있다.It is mainly used as a blood tonic, hemostatic and antipyretic agent, and is also used for anemia, pulmonary tuberculosis, weakness, and male infertility. It has anti-wrinkle effect, whitening effect, and blood pressure lowering effect.
홍삼은 인삼의 뿌리인 수삼을 표피를 벗기지 않은 채로 증숙건조(蒸熟乾燥)의 가공 공정을 거친 것을 말한다. 진세노사이드 R0, 진세노사이드 Ra1~3, Rb1~3, Rc, Rd, Rg3, Rh2, Rs1, Rs2, 노토진세노사이드 R4(notoginsenoside R4), 인삼 사포닌 Re, Rf, Rg1~2, Rh3 및 Rh4 등 사포닌 계열을 주요성분을 함유하고 있으며, 그 외에도 당류, 효소 및 무기질 원소 등이 들어있다. Red ginseng refers to the process of steaming and drying fresh ginseng, the root of ginseng, without peeling the epidermis. Ginsenoside R0, Ginsenoside Ra1~3, Rb1~3, Rc, Rd, Rg3, Rh2, Rs1, Rs2, notoginsenoside R4 (notoginsenoside R4), ginseng saponin Re, Rf, Rg1~2, Rh3 and It contains major components of saponin, such as Rh4, and also contains saccharides, enzymes, and inorganic elements.
인삼은 대표적인 아답토젠(adaptogen)으로서, 신경계와 관련하여 중추신경흥분작용, 항피로효과가 있다. 또한, 순환계와 관련하여 혈압강하작용, 항당뇨, 콜레스테롤 대사의 개선 효과가 있으며, 면역계와 관련하여 항궤양, 항염증, 항종양 효과 등이 있다.Ginseng is a representative adaptogen, and has central nervous excitation and anti-fatigue effects in relation to the nervous system. In addition, it has an effect of lowering blood pressure, anti-diabetes, and improving cholesterol metabolism in relation to the circulatory system, and has anti-ulcer, anti-inflammatory, and anti-tumor effects related to the immune system.
갈근은 칡의 뿌리로, 푸에라린(puerarin), 다이드제인(daidzein), 다이진(daidzin) 및 제니스테인(genistein) 등의 성분을 함유하고 있다. Brown root is the root of arrowroot and contains ingredients such as puerarin, daidzein, daidzin, and genistein.
이에 따라 항산화, 항진균, 항염증, 항암 및 간보호 기능을 나타내며, 고혈압과 같은 심혈관계 질환의 치료에 도움을 준다. 특히 뇌기능 개선에 효과적이며, 당뇨 및 콜레스테롤 감소효과도 가지고 있다.Accordingly, it exhibits antioxidant, antifungal, anti-inflammatory, anti-cancer and hepatoprotective functions, and helps in the treatment of cardiovascular diseases such as hypertension. In particular, it is effective in improving brain function, and has the effect of reducing diabetes and cholesterol.
복령은 소나무에 기생하는 균체로, 식감은 약간 텁텁하고 부드럽고 맛은 달고 밋밋하다. 이뇨, 억균작용, 진정작용, 장관이완작용, 혈당강하작용, 면역증강작용 및 항종양작용 등이 있다.Bokryeong is a fungus parasitic to pine trees, and the texture is slightly thick and soft, and the taste is sweet and flat. Diuresis, suppression, sedation, intestinal relaxation, blood sugar lowering, immunity enhancing and anti-tumor effects.
구기자는 구기자 나무 또는 영하구기의 열매이다. 베타인(betaine), 세레브로시드(cerebroside), 제아잔틴(zeaxanthin), 피살리엔(physalien) 등의 카로티노이드, 다양한 피롤(Phyrrole) 유도체들, 사이퍼론(cyperone), 비타민 B1, 디하이드로액티니딘(dehydroactinidiolide), 사프라날(safranal), 베타-이오논(β-ionone), 메가스티그마트리에논(megastigmatrienone), 3-하이드록시-베타-이오논(3-hydroxy-β-ionone), 스코폴레틴(scopoletin), N9-포밀하르만(N9-formylharman), 1-카보메톡시-베타-카르볼린(1-carbomethoxy-β-carboline),Goji is the fruit of the goji tree or subzero goji. Carotenoids such as betaine, cerebroside, zeaxanthin, and physalien, various pyrrole derivatives, cyperone, vitamin B1, dihydroactinidine (dehydroactinidiolide), safranal, beta-ionone, megastigmatrienone, 3-hydroxy-beta-ionone, sco Scopoletin, N9-formylharman, 1-carbomethoxy-beta-carboline,
페르롤린(perlolyrine) 등의 알칼로이드 및 베타인 등의 성분을 포함한다.It contains components such as alkaloids such as perlolyrine and betaine.
콜린대사물질의 하나인 베타인은 지방간을 억제하고, 혈중 중성지방의 농도를 저하시키며, 간신장세포의 삼투압을 조절한다. 또한, 구기자는 항산화 활성 및 CYP2E1 발현 억제를 하여 간손상억제 작용을 한다. 이 밖에도 인슐린 저항성 억제 및 당뇨병 개선, 면역 촉진, 항노화작용, 항동맥경화작용, 여성호르몬유사작용, 항종양작용 및 조혈기능촉진작용을 한다. 또한, 구기자는 발효가 이루어짐에 따라 유산균의 발육을 촉진할 수 있다.Betaine, one of the choline metabolites, inhibits fatty liver, lowers the concentration of triglycerides in the blood, and regulates the osmotic pressure of hepatic kidney cells. In addition, goji japonica acts to inhibit liver damage by inhibiting antioxidant activity and CYP2E1 expression. In addition, it suppresses insulin resistance and improves diabetes, promotes immunity, anti-aging, anti-arteriosclerosis, female hormone-like action, anti-tumor action and hematopoietic function. In addition, as the fermentation takes place, goji can promote the growth of lactic acid bacteria.
창출은 삽주의 뿌리로, 맛이 맵고 쓰다. 위장을 튼튼하게 하고 비만을 방지하고 신장 보호, 소변 배출 등을 도와주며 피로와 갈증을 없애고, 몸속의 독과 통증을 없애는 효능을 가진다.Creation is the root of sapju, and the taste is spicy and bitter. It strengthens the stomach, prevents obesity, protects the kidneys, helps to excrete urine, and has the effect of eliminating fatigue and thirst, and eliminating poison and pain in the body.
홍국은 누룩 곰팡이로 발효시켜 만든 붉은색 쌀이다. 막걸리와 흡사한 누룩 향을 가지며, 약성이 온화하고 독성이 없어, 소화불량과 설사를 다스리고 혈액순환을 촉진하며 소화 기능을 튼튼하게 한다. 또한 콜레스테롤을 저하시킨다.Hongguk is red rice made by fermentation with yeast fungus. It has a koji scent similar to makgeolli, is mild and non-toxic, relieves indigestion and diarrhea, promotes blood circulation, and strengthens digestive function. It also lowers cholesterol.
생강은 매운맛과 향긋한 냄새를 가지며, 위액분비촉진, 소화력 증진, 심장흥분 작용, 혈액순환촉진 및 억균 작용 등을 한다.Ginger has a spicy taste and fragrant odor, and promotes secretion of gastric juice, improves digestion, excites the heart, promotes blood circulation, and inhibits it.
천마는 난초과에 속하는 여러해살이 풀로, 감자와 같은 괴경으로 되어있다. 광합성이 불가한 특성이 있고 뿌리도 없어, 기생하는 담자균류인 뽕나무 버섯 속 곰팡이(Armillaria Mellea)로부터 영양을 공급받아 성장한다. Chunma is a perennial herb belonging to the Orchidaceae family, and is made of tubers like potatoes. It has properties that cannot be photosynthesized and does not have roots, so it grows by receiving nutrients from the parasitic basidiomycete, Armillaria Mellea.
천마의 대표 성분으로는 가스트로딘(gastrodin) 및 파르시닌 C(Parishin C) 등이 있다. 전통적으로 항간질약으로 사용되었으며, 특히, 기억력 향상, 치매 예방, 혈액순환 촉진, 항경련 작용, 혈압강하 및 항산화 작용을 한다. Representative ingredients of Chunma include gastrodin and Parsinin C. Traditionally, it has been used as an antiepileptic drug, and in particular, it improves memory, prevents dementia, promotes blood circulation, has anticonvulsant action, lowers blood pressure, and has antioxidant properties.
본 발명의 상기 한약재분말은 구체적으로 약재 100 중량부에 대하여, 침향 3 내지 9 중량부, 초석잠 6 내지 18 중량부, 포공영 2 내지 6 중량부가 포함되도록 하는 것이 바람직하다. It is preferable that the herbal medicine powder of the present invention specifically includes 3 to 9 parts by weight of acupuncture, 6 to 18 parts by weight of Choseokjam, and 2 to 6 parts by weight of Pogongyeong, based on 100 parts by weight of the medicinal material.
또한, 상기 한약재분말은 약재 100 중량부에 대하여, 청국장발효분말 2 내지 6 중량부, 녹용발효농축분말 5 내지 15 중량부, 산수유 5 내지 15 중량부, 당귀 5 내지 15 중량부, 진피 4 내지 12 중량부, 길경 2 내지 6 중량부, 오미자 2 내지 6 중량부, 숙지황 2 내지 6 중량부, 홍삼 2 내지 6 중량부, 갈근 2 내지 6 중량부, 복령 2 내지 6 중량부, 구기자 2 내지 6 중량부, 창출 2 내지 4 중량부, 홍국 2 내지 4 중량부, 생강 3 내지 7 중량부 및 천마 1 내지 3 중량부로 이루어진 군에서 선택된 어느 하나가 더 포함될 수 있다.In addition, the herbal medicine powder is based on 100 parts by weight of the medicinal material, 2 to 6 parts by weight of cheonggukjang fermented powder, 5 to 15 parts by weight of antler fermented concentrated powder, 5 to 15 parts by weight of cornus oil, 5 to 15 parts by weight of Angelicae, 4 to 12 parts by weight of the dermis Parts by weight, Gilkyung 2 to 6 parts by weight, Schisandra chinensis 2 to 6 parts by weight, Sukjihwang 2 to 6 parts by weight, Red ginseng 2 to 6 parts by weight, Galgeun 2 to 6 parts by weight, Bokryeong 2 to 6 parts by weight, Gugija 2 to 6 parts by weight Any one selected from the group consisting of parts, creation 2 to 4 parts by weight, hongguk 2 to 4 parts by weight, 3 to 7 parts by weight of ginger, and 1 to 3 parts by weight of cheonma may be further included.
본 발명에서 발효 효율을 향상시키기 위하여 포함된 복합발효분말은 효모 및 고초균으로 이루어진 군에서 선택된 어느 하나 이상으로 발효시키는 것이 바람직하다. In the present invention, the compound fermented powder contained in order to improve fermentation efficiency is preferably fermented with at least one selected from the group consisting of yeast and Bacillus bacillus.
바람직하게는, 상기 효모가 사카로마이세스속(Saccharomyces,sp.), 시조사카로마이세스속(Shizosaccharomyces,sp.) 및 클루레로 마이세스 속(Klureromyces sp.)으로 이루어진 군에서 선택된 어느 하나 이상일 수 있다.Preferably, the yeast is any one selected from the group consisting of Saccharomyces, sp. , Shizosaccharomyces, sp. , and Klureromyces sp. It can be more than that.
구체적으로, 상기 효모는 사카로마이세스세레비지애(Saccharomycescerevisiae), 시조사카로마이세스폼베(Schizosaccharomycespombe), 클루레로마이세스락티스(Klureromyceslactis) 및 사카로마이세스보울라디(Saccharomyces boulardii)로 이루어진 군에서 선택된 어느 하나 이상이 포함될 수 있다.Specifically, the yeast is Saccharomyces cerevisiae (Saccharomycescerevisiae), Shijo caromyces pombe (Schizosaccharomycespombe ), Klureromyces lactis (Klureromyceslactis) and Saccharomyces boulardii (Saccharomyces boulardii). Any one or more selected from the group may be included.
본 발명의 발효안심침향단은 상기 효모 및 고초균의 먹이로서 신곡을 포함한다. The fermented relief acupuncture of the present invention contains new grains as food for the yeast and Bacillus bacillus.
신곡은 주로 전통적인 방법으로 술을 빚는 데 쓰는 천연발효제로, 밀, 쌀이나 찐 콩 등 곡류를 띄워 누룩균으로 발효시킨 것이다. 일명 신국, 누룩이라고도 불리운다. New grain is a natural fermentation agent mainly used to make alcohol in the traditional way. It is fermented with yeast by floating grains such as wheat, rice or steamed beans. It is also called the so-called Shinguk or Nuruk.
신곡에는 다양한 효모균이 포함되어 있으며, 정유, 배당체, 지방유 및 비타민 B 등의 성분도 들어있다. 한방에서는 주로 소화제로 쓰인다. 소화기관을 튼튼하게 해주고, 섭취 시 소화를 촉진시키는 작용이 있다. 급체, 복통, 황달, 위경련 등에도 사용될 수 있다. New grains contain various yeast bacteria, and contain ingredients such as essential oils, glycosides, fatty oils, and vitamin B. In oriental medicine, it is mainly used as a digestive agent. It strengthens the digestive system and promotes digestion when ingested. It can also be used for sudden body, abdominal pain, jaundice, and stomach cramps.
신곡은 효모 및 고초균의 먹이 역할로서 균의 발육을 도와 발효과정이 촉진되도록 한다. 또한, 본 발명이 개시하는 발효안심침향단의 소화와 유효성분의 흡수를 용이하게 한다. New grains serve as food for yeast and Bacillus bacillus, helping the growth of bacteria and promoting the fermentation process. In addition, it facilitates the digestion and absorption of active ingredients of the fermented relief acupuncture stage disclosed by the present invention.
복합발효분말 및 신곡의 조합은 발효 효율을 보다 향상시킬 수 있다. 발효가 활성화되면 발효안심침향단의 영양성분은 더욱 강화되며, 치매에 유효한 성분의 흡수를 극대화할 수 있으며, 한약재 쓴맛과 특유의 향이 저감되고 위, 간, 장의 부담을 덜어 섭취자의 복용을 용이하게 한다.The combination of the complex fermented powder and the new grain can further improve the fermentation efficiency. When fermentation is activated, the nutrients of the fermented safe acupuncture are further strengthened, and the absorption of effective ingredients for dementia can be maximized, the bitter taste and peculiar aroma of the herbal medicine are reduced, and the burden on the stomach, liver, and intestines is relieved, making it easier for the intaker to take. do.
본 발명은 복합발효분말 및 신곡 이외에도, 정제수, 프락토올리고당 또는 유기농 비정제설탕을 더 추가할 수 있다. In the present invention, in addition to the complex fermented powder and new grains, purified water, fructooligosaccharide or organic unrefined sugar may be further added.
프락토올리고당 및 유기농 비정제설탕은 발효과정에서 발효균들의 활발한 활동을 돕는 역할을 한다. 구체적으로, 이들은 유익균의 먹이가 되어주어, 균의 생육을 촉진할 수 있다. 또한, 본 발명이 개시하는 발효안심침향단의 소화 및 흡수를 용이하게 한다. Fructoligosaccharides and organic unrefined sugars play a role in helping fermenting bacteria to actively work during the fermentation process. Specifically, they serve as food for beneficial bacteria and can promote the growth of bacteria. In addition, it facilitates the digestion and absorption of the fermented relief acupuncture stage disclosed by the present invention.
사람의 장 속에 서식하는 미생물 수는 대략 100~700조개인데, 이들 미생물의 주된 먹이는 포도당이다. 올리고당 또는 비정제설탕을 섭취할 경우, 이는 소장에서 분해되지 않고 대장까지 이동되어, 대장 유익균의 좋은 먹이가 된다. 결국 대장 유익균의 양을 유지 또는 증가시켜 장 운동을 활성화시켜 소화 및 흡수를 용이하게 한다. The number of microorganisms living in the human intestine is about 100 to 700 trillion, and the main food for these microorganisms is glucose. When ingesting oligosaccharides or unrefined sugar, it is not decomposed in the small intestine and is transferred to the large intestine, making it a good food for the beneficial colonies. Eventually, by maintaining or increasing the amount of beneficial bacteria in the intestine, it activates intestinal movement to facilitate digestion and absorption.
본 발명은 발효안심침향단의 제조방법을 제공한다. The present invention provides a method of manufacturing a fermented safe acupuncture dan.
구체적으로, 석창포, 백복신, 원지 및 형개수로 이루어진 군에서 선택된 적어도 어느 하나 이상의 약재를 이용하여 추출농축액을 획득하는 제1단계; Specifically, the first step of obtaining an extract concentrate using at least one or more medicinal materials selected from the group consisting of Seokchangpo, Baekbokshin, Wonji, and Hyunggae;
상기 추출농축액에, 침향, 초석잠 및 포공영을 함유하는 한약재분말, 복합발효분말 및 신곡을 반죽하여 혼합 발효하는 제2단계; A second step of kneading and fermenting the herbal medicine powder, complex fermented powder and new grains containing acupuncture, choseokjam and pogongyeong in the extract concentrate;
상기 발효된 반죽을 건조시키고 분쇄하여 발효약재분말을 획득하는 제3단계; 및 A third step of drying and pulverizing the fermented dough to obtain a fermented medicinal powder; And
상기 발효약재분말과 꿀을 배합하여 제환하는 제4단계를 포함한다. It includes a fourth step of blending the fermented medicinal powder and honey to make a ring.
본 발명은 발효안심침향단의 제조방법에 있어서, 제1단계는 석창포, 백복신, 원지 및 형개수로 이루어진 군에서 선택된 적어도 어느 하나 이상의 약재를 이용하여 추출농축액을 획득하는 단계로, 약재를 전탕한 후 약재와 탕액을 분리한 다음, 상기 탕액을 농축하여 추출농축액을 획득한다.In the present invention, in the method of manufacturing a fermented relief acupuncture, the first step is to obtain an extract concentrate using at least one or more medicinal materials selected from the group consisting of Seokchangpo, Baekbokshin, Wonji, and Hyeonggaesu. After separating the medicinal material and the tang liquid, the tang solution is concentrated to obtain an extract concentrate.
상기 약재는 석창포, 백복신, 원지 및 형개수로 이루어진 군에서 선택된 적어도 어느 하나 이상을 포함할 수 있다. 본 발명의 실시예에 따르면 석창포 20 내지 40중량%, 백복신 20 내지 40중량%, 원지 20 내지 40중량% 및 형개수 5 내지 10중량%로 구성된 약재를 이용하여 추출농축액을 제조한다.The medicinal material may include at least one or more selected from the group consisting of Seokchangpo, Baekbokshin, Wonji, and Hyunggaesu. According to an embodiment of the present invention, an extract concentrate is prepared using a medicinal material consisting of 20 to 40% by weight of seokchangpo, 20 to 40% by weight of baekbokshin, 20 to 40% by weight of the base paper, and 5 to 10% by weight of the number of molds.
치매에 각기 다른 유효한 성분을 가지는 석창포, 백복신, 원지 및 형개수를 균일하게 배합시킴으로써, 다양한 원인과 병변을 띠는 치매 군에 대한 포괄적인 치료 효과를 제시할 수 있다. 또한, 상기 배합을 통하여 조기치매 완화 및 예방에 관한 효능을 높일 수 있다. By uniformly mixing Seokchangpo, Baekbokshin, Wonji, and Hyeonggaesu, which have different effective ingredients for dementia, it is possible to present a comprehensive treatment effect for the dementia group with various causes and lesions. In addition, it is possible to increase the efficacy in relieving and preventing early dementia through the above combination.
석창포와 원지가 각각 20 내지 40중량% 범위를 벗어날 경우, 기억력 개선 또는 치매예방 효과가 저하될 수 있다. 백복신이 20중량%보다 적을 경우, 신경안정 효과가 떨어질 수 있으며, 40중량%를 초과할 경우 소변이 과다하게 나올 수 있다. 형개수가 5 내지 10중량% 범위를 벗어날 경우, 전체적인 배합비가 깨져 기억력 개선 및 치매예방 효과가 떨어질 수 있다.When the seokchangpo and the base paper are out of the range of 20 to 40% by weight, respectively, the memory improvement or dementia prevention effect may be lowered. If the amount of Baekbokshin is less than 20% by weight, the nerve stabilizing effect may decrease, and if it exceeds 40% by weight, excessive urine may come out. If the number of molds is out of the range of 5 to 10% by weight, the overall blending ratio may be broken, resulting in a decrease in memory improvement and dementia prevention effect.
제1단계에 있어서, 전탕기에 약재를 넣을 때 약재의 중량 대비 8 내지 11 배수의 정제수를 첨가해주는 것이 바람직하다. 정제수 양은 건조 상태의 약재가 물을 흡수하는 정도(흡수도)와, 가열과정에서 물이 증발하는 양(증발량)을 모두 고려해야 한다. In the first step, it is preferable to add purified water of 8 to 11 times the weight of the medicine when putting the medicine into the water heater. The amount of purified water should take into account both the degree to which the dried medicinal material absorbs water (absorption) and the amount by which water evaporates (evaporation) during the heating process.
첨가된 정제수 양이 약재 중량의 8배 미만일 경우, 유효성분이 완전히 침출되지 못하며, 물의 증발과정에서 유효성분이 파괴될 수 있다. 반면에, 첨가된 정제수가 약재 중량의 10배 초과일 경우, 유효성분의 추출률은 증가할 수 있으나 그 이후 농축 시간이 오래 걸리고, 유효성분 함량 또한 낮아져 기능성이 저하된다.If the amount of purified water added is less than 8 times the weight of the medicine, the active ingredient may not be completely leached, and the active ingredient may be destroyed during the evaporation of water. On the other hand, when the added purified water exceeds 10 times the weight of the medicine, the extraction rate of the active ingredient may increase, but after that, it takes a long time to concentrate and the content of the active ingredient is also lowered, resulting in a decrease in functionality.
제1단계에 있어서, 전탕기에 약재와 정제수를 넣고 나면, 본 실시예에 따라 80 내지 100℃에서 100 내지 150분동안 전탕하는 것이 바람직하다. In the first step, after putting the medicine and purified water in a water heater, it is preferable to hot water for 100 to 150 minutes at 80 to 100°C according to this embodiment.
상기와 같은 전탕 온도로 진행할 경우, 확산 속도가 향상되어 유효성분 추출률이 높아질 수 있기 때문이다. This is because when proceeding to the heating temperature as described above, the diffusion rate may be improved and the extraction rate of the active ingredient may be increased.
전탕 온도가 80℃ 미만이면 추출 효율이 저하되어 탕액에 유효성분이 부족할 수 있으며, 미생물 증식 가능성 또한 높아질 위험이 있다. 반면 100℃ 초과일 경우 살균 면에서는 효과적일 수 있으나, 단백질이나 교질 등이 파괴되거나 전분이나 섬유질과 같은 효능과 관계없는 불필요한 성분의 용출이 발생하여 약재의 효능이 저하될 수 있다.If the hot water temperature is less than 80°C, the extraction efficiency is lowered, so that the active ingredient may be insufficient in the hot water, and there is a risk that the possibility of microbial growth is also increased. On the other hand, when the temperature exceeds 100°C, it may be effective in terms of sterilization, but the efficacy of the medicinal material may be degraded due to destruction of proteins or colloids, or elution of unnecessary components not related to the efficacy such as starch or fiber.
또한, 상기 100 내지 150분의 시간 범위 안에서 전탕을 수행하도록 한다. 이는 시간적, 경제적 및 효능적 측면에서 바람직하다. 유효성분의 추출률 뿐 아니라 추출액의 향미, 색깔, 맛 및 당도(brix)를 고려했을 때에도 상기 범위가 이상적이다. In addition, the hot water is performed within the time range of 100 to 150 minutes. This is desirable in terms of time, economy and efficacy. The above range is ideal when considering not only the extraction rate of the active ingredient but also the flavor, color, taste, and brix of the extract.
이때, 상기 전탕 시간이 100분 미만일 경우 추출률이 저하될 수 있다. 150분 초과일 경우 약재의 유효성분이 온전하게 추출되지 못한다. 특히, 정유성분이나 특정 화합물은 오랜 시간 추출함에 따라 파괴되는 성질이 있기 때문에, 적정한 전탕 시간을 유지하는 것은 약재의 유효성분을 높일 수 있는 중요한 요소이다.In this case, when the heating time is less than 100 minutes, the extraction rate may decrease. If it exceeds 150 minutes, the active ingredients of the medicinal herb cannot be completely extracted. In particular, since essential oil components or specific compounds have the property of being destroyed by extraction for a long time, maintaining an appropriate heating time is an important factor that can increase the active ingredients of medicinal materials.
약재를 전탕한 후 약재와 탕액을 분리하도록 한다. 이때, 탕액은 약재 총량의 2 내지 3배수로 농축하는 것이 바람직하다. 예를 들어, 약재 1kg을 기준으로 약재를 전탕해 얻은 탕액을 2000 내지 3000cc의 추출농축액으로 농축하도록 한다. After boiling the medicinal material, separate the medicinal material from the bath liquid. At this time, it is preferable to concentrate the bath liquid to 2 to 3 times the total amount of the medicine. For example, on the basis of 1 kg of medicinal herbs, the bath liquid obtained by defrosting medicinal herbs is concentrated into an extract of 2000 to 3000 cc.
제2단계는 제1단계에서 획득한 추출농축액에, 침향, 초석잠 및 포공영을 함유하는 한약재분말, 복합발효분말 및 신곡을 반죽하여 혼합 발효하는 단계를 뜻한다. The second step refers to a step of mixing and fermenting the extract obtained in the first step by kneading the herbal medicine powder, complex fermented powder and new grains containing acupuncture, choseokjam and pogongyeong.
여기서 침향, 초석잠 및 포공영을 함유하는 한약재분말은 청국장발효분말, 녹용발효농축분말, 산수유, 당귀, 진피, 길경, 오미자, 숙지황, 홍삼, 갈근, 복령, 구기자, 창출, 홍국, 생강, 천마로 이루어진 군에서 선택된 어느 하나 이상이 더 혼합될 수 있다. 상기 한약재분말의 구성이 모두 포함되는 것이 탁월한 효능 구현을 위해 이상적일 수 있으나, 이에 한정하지 아니한다. Here, the herbal medicinal powder containing acupuncture, choseokjam and pogongyeong is cheonggukjang fermented powder, antler fermented concentrated powder, cornus milk, angelica, dermis, gilgyeong, schisandra chinensis, sukjihwang, red ginseng, galgeun, bokryeong, gugija, creation, hongguk, ginger, cheonmaro. Any one or more selected from the group consisting of may be further mixed. It may be ideal for realizing excellent efficacy that all the composition of the herbal medicine powder is included, but is not limited thereto.
구체적으로, 상기 한약재분말은 본 실시예에 따르면 약재 100 중량부에 대하여, 침향 3 내지 9 중량부, 초석잠 6 내지 18 중량부, 포공영 2 내지 6 중량부가 포함되도록 하는 것이 바람직하다. Specifically, it is preferable that the herbal medicine powder contains 3 to 9 parts by weight of acupuncture, 6 to 18 parts by weight of Choseokjam, and 2 to 6 parts by weight of Pogongyeong, based on 100 parts by weight of the medicinal material according to this embodiment.
또한, 상기 한약재분말은 약재 100 중량부에 대하여, 청국장발효분말 2 내지 6 중량부, 녹용발효농축분말 5 내지 15 중량부, 산수유 5 내지 15 중량부, 당귀 5 내지 15 중량부, 진피 4 내지 12 중량부, 길경 2 내지 6 중량부, 오미자 2 내지 6 중량부, 숙지황 2 내지 6 중량부, 홍삼 2 내지 6 중량부, 갈근 2 내지 6 중량부, 복령 2 내지 6 중량부, 구기자 2 내지 6 중량부, 창출 2 내지 4 중량부, 홍국 2 내지 4 중량부, 생강 3 내지 7 중량부 및 천마 1 내지 3 중량부로 이루어진 군에서 선택된 어느 하나가 더 포함될 수 있다.In addition, the herbal medicine powder is based on 100 parts by weight of the medicinal material, 2 to 6 parts by weight of cheonggukjang fermented powder, 5 to 15 parts by weight of antler fermented concentrated powder, 5 to 15 parts by weight of cornus oil, 5 to 15 parts by weight of Angelicae, 4 to 12 parts by weight of the dermis Parts by weight, Gilkyung 2 to 6 parts by weight, Schisandra chinensis 2 to 6 parts by weight, Sukjihwang 2 to 6 parts by weight, Red ginseng 2 to 6 parts by weight, Galgeun 2 to 6 parts by weight, Bokryeong 2 to 6 parts by weight, Gugija 2 to 6 parts by weight Any one selected from the group consisting of parts, creation 2 to 4 parts by weight, hongguk 2 to 4 parts by weight, 3 to 7 parts by weight of ginger, and 1 to 3 parts by weight of cheonma may be further included.
본 발명의 복합발효분말은 효모 및 고초균으로 이루어진 군에서 선택된 어느 하나 이상인 것을 특징으로 한다. The complex fermented powder of the present invention is characterized in that at least one selected from the group consisting of yeast and Bacillus bacillus.
바람직하게는, 상기 효모가 사카로마이세스속(Saccharomyces,sp.), 시조사카로마이세스속(Shizosaccharomyces,sp.) 및 클루레로 마이세스 속(Klureromyces sp.)으로 이루어진 군에서 선택된 어느 하나 이상인 것을 특징으로 한다. Preferably, the yeast is any one selected from the group consisting of Saccharomyces, sp. , Shizosaccharomyces, sp. , and Klureromyces sp. It is characterized by the above.
구체적으로, 상기 효모는 사카로마이세스세레비지애(Saccharomycescerevisiae), 시조사카로마이세스폼베(Schizosaccharomycespombe), 클루레로마이세스락티스(Klureromyceslactis), 사카로마이세스보울라디(Saccharomyces boulardii)로 이루어진 군에서 선택된 어느 하나 이상을 포함한다.Specifically, the yeast is Saccharomyces cerevisiae (Saccharomyces cerevisiae), Shijo caromyces pombe (Schizosaccharomycespombe ), Klureromyces lactis (Klureromyceslactis), Saccharomyces boulardii (Saccharomyces boulardii). Includes any one or more selected from the group.
이와 같이 구성된 복합발효분말을 이용하여 발효시킴으로써, 발효 효율이 보다 향상될 수 있다.By fermenting using the composite fermented powder configured as described above, fermentation efficiency can be further improved.
본 실시예에 따라 추출농축액 100 중량부에 대하여, 복합발효분말은 1 내지 3 중량부로 혼합되는 것이 바람직하다. 보다 바람직하게는 추출농축액 100 중량부 대비, 복합발효분말 2 중량부로 혼합되도록 한다. According to this embodiment, with respect to 100 parts by weight of the extract concentrate, the complex fermented powder is preferably mixed in an amount of 1 to 3 parts by weight. More preferably, it is mixed with 2 parts by weight of the complex fermented powder relative to 100 parts by weight of the extract concentrate.
이때, 상기 복합발효분말이 1 중량부 미만일 경우 발효균수가 부족할 수 있으며, 발효에 의한 유효성분 함량 증가 또한 미미할 수 있다. 3 중량부 초과일 경우에는 발효균이 과잉 증식하거나, 유효성분 함량이 목표치에 도달하지 못하여 효능이 저하될 수 있다. In this case, when the amount of the complex fermented powder is less than 1 part by weight, the number of fermenting bacteria may be insufficient, and an increase in the content of active ingredients by fermentation may also be insignificant. If it exceeds 3 parts by weight, the fermentation bacteria may proliferate excessively, or the content of the active ingredient may not reach the target value, resulting in a decrease in efficacy.
본 발명의 발효안심침향단은 상기 효모 및 고초균의 먹이로서 신곡을 포함한다. The fermented relief acupuncture of the present invention contains new grains as food for the yeast and Bacillus bacillus.
신곡은 균의 발육을 도와 발효과정이 더욱 활성화되도록 하며, 본 발명이 개시하는 발효안심침향단의 소화와 유효성분의 흡수를 용이하게 한다. 본 실시예에 따르면 추출농축액 100 중량부에 대하여, 신곡이 10 내지 30 중량부로 혼합되도록 하는 것이 바람직하다. The new grain helps the growth of bacteria to further activate the fermentation process, and facilitates the digestion and absorption of active ingredients by the fermentation safe acupuncture stage disclosed by the present invention. According to this embodiment, it is preferable to mix 10 to 30 parts by weight of new grains based on 100 parts by weight of the extract concentrate.
본 발명은 발효 효율의 향상을 위하여, 복합발효분말 및 신곡 이외에도, 정제수, 프락토올리고당 또는 유기농 비정제설탕을 더 추가할 수 있다. In the present invention, in order to improve fermentation efficiency, in addition to the complex fermented powder and new grains, purified water, fructooligosaccharide or organic unrefined sugar may be further added.
발효가 활성화되면 발효안심침향단의 영양성분은 더욱 강화되며, 치매에 유효한 성분의 흡수를 극대화할 수 있으며, 한약재 쓴맛과 특유의 향이 저감되고 위, 간, 장의 부담을 덜어 섭취자의 복용을 용이하게 한다. When fermentation is activated, the nutrients of the fermented safe acupuncture are further strengthened, and the absorption of effective ingredients for dementia can be maximized, the bitter taste and peculiar aroma of the herbal medicine are reduced, and the burden on the stomach, liver, and intestines is relieved, making it easier for the intaker to take. do.
제2단계에서는 액상인 상기 추출농축액과 고상인 상기 한약재분말, 복합발효분말 및 신곡을 배합하여 혼합 발효를 수행하는 것을 특징으로 한다. In the second step, mixed fermentation is performed by combining the liquid extract and the solid herbal medicine powder, complex fermentation powder, and new grains.
한약은 기능성에 비해 쓴맛과 특유의 향 때문에 사용량에 한계가 있어왔다. 또한, 음료 및 엑기스 등 제형 변화가 어렵다는 문제도 있다. Herbal medicine has been limited in its use due to its bitter taste and peculiar aroma compared to its functionality. In addition, there is a problem in that it is difficult to change the formulation such as beverages and extracts.
이를 극복하기 위한 방법의 일환으로서, 본 발명은 한약의 효능, 효과의 극대화 및 복용편의성을 위하여 혼합 발효를 수행하도록 한다. As part of a method for overcoming this, the present invention is to perform mixed fermentation for maximizing the efficacy and effect of the herbal medicine, and for ease of administration.
구체적으로, 혼합 발효는 본 실시예에 따라 30 내지 50℃에서 48 내지 96시간동안 수행하는 것이 바람직하다. 더욱 바람직하게는 37 내지 43℃에서 발효하는 것이며, 가장 바람직하게는 40℃에서 72시간 동안 실시하는 것이다. Specifically, the mixed fermentation is preferably performed at 30 to 50° C. for 48 to 96 hours according to this embodiment. More preferably, fermentation is performed at 37 to 43°C, and most preferably at 40°C for 72 hours.
상기 30 내지 50℃의 온도 조건은 구체적으로, 고체 발효가 수행될 수 있는 적절한 범위이다. 고체 발효는 취급이 용이한 온도에서 발효를 수행할 수 있어 공정의 편의성을 제공할 수 있다. Specifically, the temperature condition of 30 to 50°C is an appropriate range in which solid fermentation can be performed. Solid fermentation may provide convenience of a process since fermentation can be performed at a temperature that is easy to handle.
이때, 상기 발효 온도 및 시간이 상기 범위 미만일 경우 발효균주가 미흡할 수 있고, 초과일 경우 발효균주가 미흡하거나 사멸이 이루어질 수 있다. 30 내지 50℃에서 48 내지 96시간동안이라는 발효 조건을 통해 한약재 쓴맛과 특유의 향을 저감 시킬 수 있으며, 유효성분 및 그의 흡수율을 높일 수 있다. In this case, when the fermentation temperature and time are less than the above range, the fermentation strain may be insufficient, and when it is exceeded, the fermentation strain may be insufficient or death. Through the fermentation conditions of 48 to 96 hours at 30 to 50° C., the bitter taste and peculiar aroma of the herbal medicine can be reduced, and the active ingredient and its absorption rate can be increased.
제2단계는 혼합 발효 전에 멸균단계를 더 추가할 수 있다. 상기 멸균은 115 내지 121℃에서 10 내지 20분동안 이루어질 수 있고, 바람직하게는 121℃에서 15분동안 수행하도록 한다. The second step may further add a sterilization step before the mixed fermentation. The sterilization may be performed at 115 to 121°C for 10 to 20 minutes, and preferably at 121°C for 15 minutes.
제3단계는 발효된 반죽을 건조시키고 분쇄하여 발효약재분말을 획득하는 것이다. 발효된 반죽의 수분함량을 감소시켜 분말로 제조하기 위하여, 본 실시예에 따라 50 내지 60℃에서 8 내지 12시간동안 건조시키도록 한다. 바람직하게는 60℃에서 10시간동안 실시할 수 있다. The third step is to dry and crush the fermented dough to obtain fermented medicinal powder. In order to reduce the moisture content of the fermented dough to produce a powder, it is dried for 8 to 12 hours at 50 to 60°C according to this embodiment. Preferably, it can be carried out at 60° C. for 10 hours.
여기서, 건조 온도 및 시간이 8시간, 50℃미만일 경우, 건조가 충분히 되지 않아 분말화 작업이 어려울 수 있다. 또한, 12시간, 60℃ 초과일 경우 발효균주가 사멸하고 유효성분의 손실이 일어날 수 있다.Here, when the drying temperature and time are less than 8 hours and 50° C., the drying may not be sufficient and thus the powdering operation may be difficult. In addition, if it exceeds 12 hours and 60 ℃, the fermentation strain may be killed and the loss of active ingredients may occur.
건조시킨 결과물은 수분함량이 8% 이하인 것이 바람직하며, 보다 바람직하게는 5% 이하인 것이다. 수분함량이 적을수록 분말화가 잘 이루어져 제4단계에서 사용되기 적합하다. The dried product preferably has a moisture content of 8% or less, and more preferably 5% or less. The smaller the moisture content, the better the powdering is, and it is suitable for use in the fourth step.
제3단계에 있어서, 건조시킨 결과물은 분쇄되어 발효약재분말로 획득될 수 있다. 본 실시예에 따르면, 상기 발효약재분말은 상기 건조시킨 결과물이 180 내지 220입도로 분쇄되어 획득된 것을 특징으로 한다. In the third step, the dried product may be pulverized to obtain a fermented medicinal powder. According to this embodiment, the fermented medicinal powder is characterized in that obtained by pulverizing the dried product into 180 to 220 particles.
제3단계는 획득된 발효약재분말을 180입도 이상의 체를 이용하여 걸러내는 단계를 더 포함할 수 있다. 선별된 발효약재분말은 제4단계에서 반죽 제조를 용이하게 하고, 성형성을 향상시킨다. The third step may further include filtering the obtained fermented medicinal powder using a sieve having a size of 180 or more. The selected fermented medicinal powder facilitates dough manufacturing in the fourth step and improves moldability.
제4단계는 제3단계에서 획득한 발효약재분말과 꿀을 배합하여 제환하는 것이다. 제4단계는 반죽단계와 성형단계로 이루어지는 것을 특징으로 한다. The fourth step is to combine the fermented medicinal powder obtained in the third step and honey to make a pill. The fourth step is characterized in that it consists of a kneading step and a molding step.
반죽단계는 제3단계에서 획득된 발효약재분말에 꿀을 배합하여 반죽하는 단계이다.The kneading step is a step of kneading by mixing honey with the fermented medicinal powder obtained in the third step.
본 실시예에 따라 발효약재분말 60 내지 90중량% 및 꿀 10 내지 40중량%을 배합하여 반죽하는 것이 바람직하다. It is preferable to mix and knead 60 to 90% by weight of fermented medicinal powder and 10 to 40% by weight of honey according to this embodiment.
발효약재분말에 꿀을 혼합함으로써 반죽이 가능하도록 하고, 성형성을 향상시키며, 약재의 쓴맛과 특유 향을 저감시킬 수 있다. By mixing honey with fermented medicinal powder, it is possible to make dough, improve moldability, and reduce the bitter taste and peculiar aroma of medicinal materials.
한약재는 기능성에 비해 쓴맛과 고유 향 때문에 사용량에 한계가 있다. 특히, 유아제품의 경우 이로 인해 복용 기호도가 낮은 문제가 있어 왔다. 한약재는 가공에 있어서도 음료 및 엑기스 등의 제형 변화에 대한 어려움이 있다. Compared to its functionality, herbal medicine has a limit on its use due to its bitter taste and unique aroma. In particular, in the case of infant products, there has been a problem of low dosage preference. In the processing of herbal medicines, there is a difficulty in changing the formulation of beverages and extracts.
이에 본 발명은 꿀을 발효약재분말과 배합함으로써, 환에 단맛을 부여하고 약재 특유의 맛과 쓴 향을 저감시켜 환의 섭취성을 향상시킨다. 나아가 환의 형태로 성형되고 유지될 수 있도록 적절한 점성을 부여할 수 있다. Accordingly, in the present invention, by blending honey with the fermented medicinal powder, sweetness is given to the pill and the unique taste and bitter aroma of the medicinal material are reduced, thereby improving the intake of the pill. Furthermore, it is possible to impart an appropriate viscosity so that it can be molded and maintained in a ring shape.
배합되는 꿀의 양이 10%이하인 경우 환이 딱딱해져 섭취가 불편해질 수 있으며, 배합되는 꿀의 양이 40%이상인 경우 제환 작업시 반죽이 기계에 들러붙거나, 포장작업시 포장지에 들러붙을 수 있다.If the amount of honey to be blended is less than 10%, the pill may become hard and ingestion may become uncomfortable.If the amount of honey to be blended is more than 40%, the dough may stick to the machine during the pulping operation or stick to the wrapping paper during packaging work. .
성형단계는 반죽단계에서 획득된 반죽을 환 형태로 성형하는 것이다. 환의 크기는 15 내지 20mm, 중량은 3 내지 5g일 수 있다. 바람직하게는 18mm, 4g으로 환을 제조하도록 한다. 성형단계는 환의 모양을 만들어 주는 과정 및 코팅하는 과정이 모두 포함되어 있을 수 있다. The molding step is to shape the dough obtained in the kneading step into a ring shape. The size of the ring may be 15 to 20 mm, and the weight may be 3 to 5 g. Preferably, to prepare a ring with 18mm, 4g. The molding step may include both the process of forming the shape of the ring and the process of coating.
최종적으로 제조된 환을 포장하도록 한다. Wrap the finally prepared pill.
이하, 실시예를 통하여 본 발명을 보다 상세히 설명하고자 한다. Hereinafter, the present invention will be described in more detail through examples.
본 실시예는 본 발명을 보다 구체적으로 설명하기 위한 것이며, 본 발명의 범위가 이들 실시예에 한정되는 것은 아니다. The present examples are for explaining the present invention in more detail, and the scope of the present invention is not limited to these examples.
<실시예 1> <Example 1>
석창포 30.8중량%, 백복신 30.8중량%, 원지 30.8중량% 및 형개수 7.6중량%의 약재를 전탕한 후 약재와 탕액을 분리하고, 탕액을 농축하여 추출농축액을 제조하였다. After boiling 30.8% by weight of Seokchangpo, 30.8% by weight of Baekbokshin, 30.8% by weight of raw paper, and 7.6% by weight of the number of molds, the medicinal material and the bath were separated, and the bath was concentrated to prepare an extract concentrate.
상기 추출농축액 9.1 중량부에 대하여, 침향 4.3 중량부, 초석잠 8.7 중량부, 포공영 2.9 중량부, 청국장발효분말 2.9 중량부, 녹용발효농축분말 7.2 중량부, 산수유 7.2 중량부, 당귀 7.2 중량부, 진피 5.8 중량부, 길경 2.9 중량부, 오미자 2.9 중량부, 숙지황 2.9 중량부, 홍삼 2.9 중량부, 갈근 2.9 중량부, 복령 2.9 중량부, 구기자 2.9 중량부, 창출 2.2 중량부, 홍국 2.2 중량부, 생강 3.6 중량부, 천마 0.7 중량부를 포함한 한약재분말, 복합발효분말 1.4중량부 및 신곡 14.4 중량부를 혼합하였다. With respect to 9.1 parts by weight of the extract concentrate, 4.3 parts by weight of acupuncture, 8.7 parts by weight of Choseokjam, 2.9 parts by weight of Pogongyeong, 2.9 parts by weight of cheonggukjang fermented powder, 7.2 parts by weight of fermented deer antler powder, 7.2 parts by weight of cornus oil, 7.2 parts by weight of angelica angelica, Dermis 5.8 parts by weight, Gilgyeong 2.9 parts by weight, Schisandra chinensis 2.9 parts by weight, Sukjihwang 2.9 parts by weight, Red ginseng 2.9 parts by weight, Galgeun 2.9 parts by weight, Bokryeong 2.9 parts by weight, Gugija 2.9 parts by weight, Jinseong 2.2 parts by weight, Hongguk 2.2 parts by weight, Ginger 3.6 parts by weight, herbal medicine powder including 0.7 parts by weight of cheonma, 1.4 parts by weight of complex fermented powder, and 14.4 parts by weight of new grain were mixed.
상기 혼합 후 40℃에서 72시간동안 고체 발효시키고, 수분함량이 5% 이하가 되도록 60℃에서 10시간동안 건조시킨 후, 180 내지 220 입도로 분쇄시켜 발효약재분말을 제조하였다. After the mixing, the solid was fermented at 40° C. for 72 hours, dried at 60° C. for 10 hours so that the moisture content was 5% or less, and then pulverized to a particle size of 180 to 220 to prepare a fermented medicinal powder.
상기 발효약재분말 80중량%에 꿀 20중량%를 혼합 반죽하고, 15∼18mm, 4∼5g의 환 형태로 성형하여 발효안심침향단을 제조하였다. The fermented medicinal powder 80% by weight and 20% by weight of honey were mixed and kneaded, and then formed into a ring shape of 15 to 18 mm and 4 to 5 g to prepare a fermented relief acupuncture.
<비교예 1> <Comparative Example 1>
석창포 30.8중량%, 백복신 30.8중량%, 원지 30.8중량% 및 형개수 7.6중량%의 약재를 전탕한 후 약재와 탕액을 분리하고, 탕액을 농축하여 추출농축액을 제조하였다. After boiling 30.8% by weight of Seokchangpo, 30.8% by weight of Baekbokshin, 30.8% by weight of raw paper, and 7.6% by weight of the number of molds, the medicinal material and the bath were separated, and the bath was concentrated to prepare an extract concentrate.
상기 발효약재분말 82.9중량%, 상기 추출농축액 5중량%, 꿀 12.1중량%을 혼합하여 반죽하고 환 형태로 성형하고 당의 후 건조시켜 환을 제조하였다. 82.9% by weight of the fermented medicinal powder, 5% by weight of the extract concentrate, and 12.1% by weight of honey were mixed, kneaded, molded into a ring, and dried after sugar to prepare a ring.
<비교예 2> <Comparative Example 2>
석창포 30.8중량%, 백복신 30.8중량%, 원지 30.8중량% 및 형개수 7.6중량%의 약재를 전탕한 후 약재와 탕액을 분리하였다. After boiling 30.8% by weight of Seokchangpo, 30.8% by weight of Baekbokshin, 30.8% by weight of raw paper, and 7.6% by weight of the number of molds, the medicine and the bathing liquid were separated.
상기 분리된 약재를 발효수와 발효시킨 후 건조하고 분쇄하여 발효약재분말을 제조하였다. 상기 발효약재분말 88.1중량%, 혼합 분말 풀 6.9중량% 및 꿀 5중량%를 혼합하여 반죽하고 환 형태로 성형하고 당의 후 건조시켜 발효 환을 제조하였다.The separated medicinal material was fermented with fermented water, dried and pulverized to prepare a fermented medicinal powder. The fermented medicinal powder 88.1 wt%, mixed powder paste 6.9 wt%, and honey 5 wt% were mixed, kneaded, molded into a ring shape, and dried after sugar to prepare a fermented pill.
<실험예 1> 관능평가<Experimental Example 1> Sensory evaluation
실시예 1, 비교예 1 및 2에 대하여 관능평가를 실시하였다.Sensory evaluation was performed for Example 1 and Comparative Examples 1 and 2.
훈련된 전문 관능검사 요원(2년 이상 관능검사 경험을 지닌 50명[남자 25명, 여자 25명]) 중 미각이 상대적으로 우수한 30명을 선발하여 맛, 향, 식감 및 기호도에 대한 정량적 묘사분석(Quantitative Descriptive Analysis: QDA)을 하였다. 관능검사는 5점 측정법(1: 매우 나쁨, 2: 나쁨, 3: 보통, 4: 좋음, 5: 매우 좋음)으로 실시하였고, 선호도 조사를 하여 평균으로 등수를 구하였다.Among trained professional sensory test personnel (50 people [25 men, 25 women] with experience in sensory testing for more than 2 years), 30 people with relatively excellent taste were selected and analyzed for quantitative description of taste, aroma, texture, and preference. (Quantitative Descriptive Analysis: QDA) was performed. The sensory test was performed with a 5-point measurement method (1: very bad, 2: bad, 3: moderate, 4: good, 5: very good), and preference was investigated and the rank was calculated as an average.
실시예 1, 비교예 1 및 2에서 하나를 섭취하여 평가한 뒤 반드시 물로 입 안을 헹군 후 다른 하나를 섭취하여 평가하는 것으로 실시하였다.In Example 1 and Comparative Examples 1 and 2, one was taken and evaluated, and then the mouth was rinsed with water, and the other was taken and evaluated.
그 결과는 하기 표 1과 같다.The results are shown in Table 1 below.
상기 표 1을 보면 알 수 있듯이, 실시예 1이 비교예 1 및 2보다 모든 항목에서 전체적으로 우수한 것을 확인할 수 있었다.As can be seen from Table 1, it was confirmed that Example 1 was superior to Comparative Examples 1 and 2 in all items as a whole.
<실험예 2> 임상실험 평가<Experimental Example 2> Clinical trial evaluation
상기 실시예 1에서 제조된 발효안심침향단에 대하여, 고령 환자를 대상으로 치매에 유효성 여부를 평가하였다. The fermented relief acupuncture dan prepared in Example 1 was evaluated for efficacy against dementia in elderly patients.
치매 증상의 하나의 지표로서, 산소와 같은 계열의 독성을 가지는 유해활성산소 수치를 측정하였다. 유해활성산소는 노화의 주요 원인 중 하나로 알려져 있으며, 인체 내 유해활성탄소 수치가 높을수록 치매, 각종 암, 혈관질환, 간염, 위염, 관절염 및 자가면역질환 등이 발생할 확률이 높다. 이때, 유해활성산소 수치가 500 미만인 경우 "정상"이라고 판단하였다. As an index of dementia symptoms, the level of harmful free radicals having the same type of toxicity as oxygen was measured. Harmful free radicals are known as one of the main causes of aging, and the higher the level of harmful activated carbon in the human body, the higher the probability of occurrence of dementia, various cancers, vascular diseases, hepatitis, gastritis, arthritis and autoimmune diseases. At this time, if the level of harmful active oxygen was less than 500, it was judged as "normal".
치매 증상에 대한 임상실험을 수행하기 위하여, 병원에 내원중인 고령 환자를 대상으로 상기 실시예 1에서 제조된 발효안심침향단을 복용시킨 후, 한국형 간이 정신상태검사(K-MMSE)법에 따른 점수를 측정하여 호전 정도를 평가하였다. 이때, K-MMSE 검사 결과는 총 30점 만점 기준으로, 14점 이하는 중증 치매, 15~19점은 경증 치매, 20~23점은 치매 의심 및 24점 이상은 정상으로 분류하였다. In order to conduct a clinical experiment on dementia symptoms, after taking the fermented relief acupuncture group prepared in Example 1 for elderly patients visiting the hospital, scores according to the Korean Simple Mental State Test (K-MMSE) method The degree of improvement was evaluated by measuring. At this time, the K-MMSE test result was based on a total of 30 points, and 14 points or less were classified as severe dementia, 15 to 19 points were mild dementia, 20 to 23 points were suspected of dementia, and 24 points or more were classified as normal.
그 결과는 하기 표 2와 같다. The results are shown in Table 2 below.
상기 7명의 환자를 대상으로(2명의 중증치매, 5명의 경증 치매) 발효안심침향단을 1일 1회씩 2달간 복용시키고, 1달에 1번씩 K-MMSE검사를 실시한 결과, 평균적으로 K-MMSE 점수가 4점씩 상승한 것을 확인할 수 있었다.In the above 7 patients (2 severe dementia, 5 mild dementia), fermented relief acupuncture group was taken once a day for 2 months, and K-MMSE test was conducted once a month. It was confirmed that the score increased by 4 points.
또한, 경증 치매환자(15점~19점)에서 의심환자로 전환된 환자의 숫자는 5명 중 3명이었으며, 나머지 2명도 각각 18점, 19점으로 기준점수인 20점에 근접한 것을 확인하였다. In addition, the number of patients converted from mild dementia patients (15 points to 19 points) to suspected patients was 3 out of 5, and the remaining 2 were also 18 points and 19 points, respectively, which was close to the standard score of 20 points.
이상의 결과로부터, 실시예 1에서 제조된 발효안심침향단은 한국형 간이 정신상태검사(K-MMSE)법에 따라, 치매 대한 우수한 효능을 확인하였다. From the above results, the fermented relief acupuncture dan prepared in Example 1 was confirmed to have excellent efficacy against dementia according to the Korean simplified mental state test (K-MMSE) method.
이상으로 첨부된 도면을 참조하여 본 발명의 실시예를 설명하였으나, 본 발명이 속하는 기술분야에서 통상의 지식을 가진 자는 본 발명의 기술적 사상이나 필수적인 특징을 변경하지 않고 다른 구체적인 형태로 실시할 수 있다는 것을 이해할 수 있을 것이다. 따라서 이상에서 기술한 실시예는 모든 면에서 예시적인 것이며 이에 한정하지 아니한다. The embodiments of the present invention have been described above with reference to the accompanying drawings, but those of ordinary skill in the art to which the present invention pertains can be implemented in other specific forms without changing the technical spirit or essential features of the present invention. You will be able to understand. Therefore, the embodiments described above are illustrative in all respects and are not limited thereto.
Claims (15)
침향, 초석잠, 포공영, 청국장발효분말, 녹용발효농축분말, 산수유, 당귀, 진피, 길경, 오미자, 숙지황, 홍삼, 갈근, 복령, 구기자, 창출, 홍국, 생강 및 천마를 함유하는 한약재분말,
효모 및 고초균으로 이루어진 군에서 선택된 어느 하나 이상 및 신곡이 혼합되어 발효 후 제환된 조기치매 완화 또는 예방용 발효안심침향단.In the extract concentrate obtained using at least one or more medicinal materials selected from the group consisting of Seokchangpo, Baekbokshin, Wonji, and Hyeonggaesu,
Acupuncture, Choseokjam, Pogongyeong, Cheonggukjang fermented powder, Deer antler fermented concentrated powder, Cornus milk, Angelicae, dermis, Gilgyeong, Schisandra chinensis, Sukjihwang, Red ginseng, Galgeun, Bokryeong, Gugija, Jeung, Hongguk, Ginger and Cheonma,
A fermented relief acupuncture for the alleviation or prevention of early dementia that is reconstituted after fermentation by mixing at least one selected from the group consisting of yeast and Bacillus bacillus.
상기 추출농축액에, 침향, 초석잠, 포공영, 청국장발효분말, 녹용발효농축분말, 산수유, 당귀, 진피, 길경, 오미자, 숙지황, 홍삼, 갈근, 복령, 구기자, 창출, 홍국, 생강 및 천마를 함유하는 한약재분말, 효모 및 고초균으로 이루어진 군에서 선택된 어느 하나 이상 및 신곡을 반죽하여 혼합 발효하는 제2단계;
상기 발효된 반죽을 건조시키고 분쇄하여 발효약재분말을 획득하는 제3단계; 및
상기 발효약재분말과 꿀을 배합하여 제환하는 제4단계를 포함하는 발효안심침향단의 제조방법.A first step of obtaining an extract concentrate using at least one or more medicinal materials selected from the group consisting of Seokchangpo, Baekbokshin, Wonji, and Hyunggae;
In the extract concentrate, acupuncture, choseokjam, pogongyeong, cheonggukjang fermented powder, antler fermented concentrated powder, cornus milk, angelica, dermis, gilkyung, schisandra chinensis, sukjihwang, red ginseng, galgeun, bokryeong, gugija, seonghwa, red ginseng, ginger and cheonma are contained. A second step of kneading and fermenting at least one selected from the group consisting of herbal medicine powder, yeast and Bacillus bacillus and kneading new grains;
A third step of drying and pulverizing the fermented dough to obtain a fermented medicinal powder; And
A method of manufacturing a fermented relief acupuncture step comprising a fourth step of blending the fermented medicinal powder and honey to make a pill.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020200112522A KR102243873B1 (en) | 2020-09-03 | 2020-09-03 | Fermented pills for reducing and preventing premature dementia and manufacturing methods thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020200112522A KR102243873B1 (en) | 2020-09-03 | 2020-09-03 | Fermented pills for reducing and preventing premature dementia and manufacturing methods thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
KR102243873B1 true KR102243873B1 (en) | 2021-04-23 |
Family
ID=75738068
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020200112522A KR102243873B1 (en) | 2020-09-03 | 2020-09-03 | Fermented pills for reducing and preventing premature dementia and manufacturing methods thereof |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR102243873B1 (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102486693B1 (en) * | 2022-08-05 | 2023-01-11 | 김성태 | Lactobacillus fermentation manufacturing method and production system to improve the absorption rate of beta-selinene contained in agarwood |
KR102582249B1 (en) * | 2022-09-27 | 2023-09-25 | 강위희 | A Brain health nutritional supplement manufacturing method using natural herbs and Stachys affinis |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100744015B1 (en) | 2006-03-06 | 2007-07-30 | 길기정 | Health drink for dementia prevention using a chinese medicine |
KR101564357B1 (en) * | 2014-05-14 | 2015-10-30 | 이창호 | Using herbal medicine prescription medicine fermented food production methods |
KR101610459B1 (en) | 2014-03-19 | 2016-04-20 | 박병준 | a natural extraction hepad X2 composition of both the protection and the treatment of the parkinson's disease |
KR20160057750A (en) * | 2014-11-14 | 2016-05-24 | 신성에프엔비 주식회사 | Method of manufacturing an oriental tea having a red ginseng |
KR101888587B1 (en) | 2017-01-04 | 2018-08-14 | 대전대학교 산학협력단 | Liquefied gongjindan composition and manufacturing method thereof |
KR101974886B1 (en) | 2017-10-20 | 2019-05-03 | 장영용 | Gongjindan for memory enhancement and learning capabilities and manufacturing method thereof |
-
2020
- 2020-09-03 KR KR1020200112522A patent/KR102243873B1/en active IP Right Grant
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100744015B1 (en) | 2006-03-06 | 2007-07-30 | 길기정 | Health drink for dementia prevention using a chinese medicine |
KR101610459B1 (en) | 2014-03-19 | 2016-04-20 | 박병준 | a natural extraction hepad X2 composition of both the protection and the treatment of the parkinson's disease |
KR101564357B1 (en) * | 2014-05-14 | 2015-10-30 | 이창호 | Using herbal medicine prescription medicine fermented food production methods |
KR20160057750A (en) * | 2014-11-14 | 2016-05-24 | 신성에프엔비 주식회사 | Method of manufacturing an oriental tea having a red ginseng |
KR101888587B1 (en) | 2017-01-04 | 2018-08-14 | 대전대학교 산학협력단 | Liquefied gongjindan composition and manufacturing method thereof |
KR101974886B1 (en) | 2017-10-20 | 2019-05-03 | 장영용 | Gongjindan for memory enhancement and learning capabilities and manufacturing method thereof |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102486693B1 (en) * | 2022-08-05 | 2023-01-11 | 김성태 | Lactobacillus fermentation manufacturing method and production system to improve the absorption rate of beta-selinene contained in agarwood |
KR102582249B1 (en) * | 2022-09-27 | 2023-09-25 | 강위희 | A Brain health nutritional supplement manufacturing method using natural herbs and Stachys affinis |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR100404979B1 (en) | Drink for getting rid of the aftereffects of the night's drink and manufacturing method thereby | |
KR102136052B1 (en) | Composition for Liver Protection Containing Hub Extract and Beverage Thereof | |
KR101855821B1 (en) | Composition for relieving of menopausal symptoms and improving blood circulation | |
KR20130056639A (en) | Health food fermented using effective micro-organisms with herbal medicine for reducing blood sugar and blood pressure and manufacturing method thereof | |
KR102243873B1 (en) | Fermented pills for reducing and preventing premature dementia and manufacturing methods thereof | |
CN106343343A (en) | Lithocarpus polystachyus (DC.) Rehd tartarian buckwheat composition for reducing three-high and application thereof | |
KR101930277B1 (en) | Composition for Preventing and Improving Hangover | |
KR20030026939A (en) | The effective tea compositions with guava leaf as chief element for remedy against diabetes, obesity and aging, and functional foods | |
KR101751211B1 (en) | Composition for improving sexual function, Functional food Composition for improving sexual function comprising of the same and Manufacturing method thereof | |
CN103749821B (en) | A kind of gynostemma pentaphylla health-care tea improving immunity and preparation method thereof | |
KR101166883B1 (en) | Composition of mixed herb medicine for leached tea | |
KR101140322B1 (en) | Composition of mixed herb medicine for leached tea | |
KR101826737B1 (en) | A composition containing herbs extract, and manufacturing method of the same | |
KR20090085236A (en) | Herbal composition for alcoholic hangover | |
KR20070097234A (en) | Lactic acid fermentation composition using edible herbs and the preparation method of thereof | |
KR100891914B1 (en) | The method of preparing the functional food for diet using extrative extrated from madicin-matrrials of plants | |
KR101788253B1 (en) | Composition for improving male sexual function comprising the extract of Alpinia Officinarum, Smilacina Japonica & Black Garlic | |
KR20170052868A (en) | Composition for eliminating hangover with medicinal herbs classified as a food ingredient and Manufacturing method thereof | |
KR20100077781A (en) | Method for preparing functional powder to improve erectile dysfunction and assistance food comprising the functional powder | |
KR20160000695A (en) | Herbal-medicine containing dha for recovering fatigue and enhancing memory, and method of manufacturing the same | |
KR20200025245A (en) | Preparation for improving blood circulation comprising mixed oriental medicinal extracts | |
KR101783549B1 (en) | Health supplement food containing dha for recovering fatigue, and method of manufacturing the same | |
KR20190062833A (en) | Method of the sprout barley mixture tea increased content of antioxidant or active ingredient of Anti-diabetic with eliminating the unpleasant odor of sprout barley, powder of silkworm and leaves of Cudrania tricuspidata | |
KR101953576B1 (en) | Functional beverage for anticancer and process for preparing the same | |
KR102215936B1 (en) | Functional Food Composition Ssangwhatang for Fatigue Recovery comprising Chestnut and Manufacturing method of thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant |